

Understanding the Dose-Effect Relationship

Clinical Pharmacokinetics

6, 429-453

DOI: 10.2165/00003088-198106060-00002

Citation Report

#	ARTICLE	IF	CITATIONS
1	Blood Loss: Does It Change My Intravenous Anesthetic?. , 0, , 133-141.		0
2	On the use of hybrid multivariable models for predicting human response to anesthesia. , 0, , .		1
3	Yohimbine both increases and decreases nociceptive thresholds in rats: Evaluation of the dose-response relationship. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 322, 193-197.	1.4	21
4	Application of effect-compartment model to bumetanide-indomethacin interaction in dogs. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 355-368.	0.6	5
5	Determinants of bumetanide response in the dog: Effect of probenecid. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 31-46.	0.6	14
6	Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers. European Journal of Clinical Pharmacology, 1983, 24, 791-796.	0.8	14
7	Opposing effects of apomorphine on pain in rats. Evaluation of the dose-response curve. European Journal of Pharmacology, 1983, 88, 27-35.	1.7	60
8	Relationship between plasma concentration and effect of midazolam after oral and intravenous administration.. British Journal of Clinical Pharmacology, 1983, 16, 51S-61S.	1.1	104
9	Statistical Methods for Bioavailability and Bioequivalence. Clinical Research Practices and Drug Regulatory Affairs, 1983, 1, 109-132.	0.0	30
10	Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 275-282.	0.6	58
11	Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 559-573.	0.6	28
12	Pharmacodynamic measurements of methyl nicotinate percutaneous absorption. Pharmaceutical Research, 1984, 01, 76-81.	1.7	45
13	Drug concentration, binding, and effect in vivo. Pharmaceutical Research, 1984, 01, 102-105.	1.7	9
14	Relationship of Morphine-Induced Miosis to Plasma Concentration in Normal Subjects. Journal of Pharmaceutical Sciences, 1984, 73, 1496-1497.	1.6	13
15	Torsade de pointes induced by N-Acetylprocainamide. Journal of the American College of Cardiology, 1984, 4, 621-624.	1.2	81
16	Prediction of response to theophylline in chronic bronchitis.. British Journal of Clinical Pharmacology, 1984, 17, 1-8.	1.1	26
17	Drugs and Exercise. Medical Clinics of North America, 1985, 69, 177-187.	1.1	20
18	Promethazine both facilitates and inhibits nociception in rats: Effect of the testing procedure. Psychopharmacology, 1985, 85, 31-36.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Disposition of Pentopril, a New Orally Active Angiotensin-Converting Enzyme Inhibitor, and Its Active Metabolite in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 947-952.	1.6	7
20	Rapid Achievement of Antidepressant Effect with Intravenous Chlorimipramine. <i>New England Journal of Medicine</i> , 1985, 312, 1130-1130.	13.9	13
21	Caffeine distribution in acute toxic response among inbred mice. <i>Toxicology Letters</i> , 1985, 29, 25-31.	0.4	0
22	Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.. <i>British Journal of Clinical Pharmacology</i> , 1985, 19, 143S-149S.	1.1	12
23	Clinical pharmacodynamics of theophylline. <i>Journal of Allergy and Clinical Immunology</i> , 1985, 76, 292-297.	1.5	20
24	The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. <i>American Heart Journal</i> , 1985, 109, 210-217.	1.2	137
25	Concentration-dependent pharmacologic properties of sotalol. <i>American Journal of Cardiology</i> , 1986, 57, 1160-1165.	0.7	99
26	Myocardial pharmacodynamics of dopamine, dobutamine, amrinone and isoprenaline compared in the isolated rabbit heart. <i>European Journal of Pharmacology</i> , 1986, 124, 51-57.	1.7	13
27	Relaxant effects of xanthines, a β_2 -receptor agonist and Ca^{2+} antagonists in guinea-pig tracheal preparations contracted by potassium or carbachol. <i>European Journal of Pharmacology</i> , 1986, 128, 33-40.	1.7	21
28	Single and combined myocardial pharmacodynamics of xamoterol, isoprenaline and g-strophanthin in the isolated rabbit heart. <i>European Journal of Pharmacology</i> , 1986, 125, 363-371.	1.7	6
29	Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201403 by an integrated pharmacokinetic-pharmacodynamic model.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 1-13.	1.1	14
30	Does the benzodiazepine antagonist Ro 151788 antagonize the action of ethanol?. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 513-520.	1.1	44
31	Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. <i>Clinical Pharmacokinetics</i> , 1986, 11, 483-504.	1.6	249
32	Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem. <i>Clinical Pharmacokinetics</i> , 1986, 11, 425-449.	1.6	172
33	L-Dopa: how it may exacerbate parkinsonian symptoms. <i>Trends in Pharmacological Sciences</i> , 1986, 7, 15-19.	4.0	16
34	Kinetics of drug action: An overview. <i>Journal of Allergy and Clinical Immunology</i> , 1986, 78, 754-761.	1.5	24
35	A strain-gauge myograph for isometric measurements of tension in isolated small blood vessels and other muscle preparations. <i>Journal of Pharmacological Methods</i> , 1986, 16, 215-225.	0.7	27
36	Verapamil Pharmacodynamics After Intravenous and Oral Dosing: Theoretic Consideration. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 71-73.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and Pharmacodynamics of Pentopril, a New Angiotensinâ€Convertingâ€Enzyme Inhibitor in Humans. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 156-164.	1.0	50
38	Design of experiments for the precise estimation of dose-response parameters: the Hill equation. <i>Journal of Theoretical Biology</i> , 1986, 123, 415-430.	0.8	44
39	Influence of intravenous infusion duration on the tissue drug concentration profile. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 323-334.	0.6	4
40	Kinetics and Dynamics of Prednisolone*. <i>Endocrine Reviews</i> , 1987, 8, 453-473.	8.9	61
41	Controversy II: Bioequivalence as an Indicator of Therapeutic Equivalence: Modeling the Theoretic Influence of Bioinequivalence on Singleâ€Dose Drug Effect. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 342-345.	1.0	8
42	Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome. <i>Gastroenterology</i> , 1987, 93, 69-76.	0.6	19
43	Pharmacodynamics. <i>Drug Intelligence & Clinical Pharmacy</i> , 1987, 21, 117-121.	0.4	0
44	RO 13â€6438 IN CONGESTIVE HEART FAILURE: DOSEâ€RESPONSE RELATIONSHIP AFTER 3 SINGLE DOSES. <i>Fundamental and Clinical Pharmacology</i> , 1987, 1, 459-470.	1.0	0
45	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. <i>Brain Research</i> , 1987, 414, 395-400.	1.1	111
46	Nifedipine. <i>Clinical Pharmacokinetics</i> , 1987, 12, 12-29.	1.6	63
47	Intravenous Anaesthetic Agents. <i>Clinical Pharmacokinetics</i> , 1987, 12, 79-110.	1.6	40
48	The Role of Pharmacokinetics in Anaesthesia: Application to Intravenous Infusions. <i>Anaesthesia and Intensive Care</i> , 1987, 15, 7-14.	0.2	6
49	Variability in drug metabolism: importance of genetic constitution. <i>Pharmaceutisch Weekblad Scientific Edition</i> , 1987, 9, 85-90.	0.9	6
50	Haemodilution therapy in ischaemic stroke: Plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. <i>European Journal of Clinical Pharmacology</i> , 1987, 31, 705-710.	0.8	44
51	Pharmacokinetics and pharmacodynamics of thiazinamium in asthmatic patients. <i>European Journal of Clinical Pharmacology</i> , 1987, 33, 237-242.	0.8	2
52	Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1987, 12, 41-48.	0.6	3
53	Benzodiazepine Receptor Binding of Triazolobenzodiazepines In Vivo: Increased Receptor Number with Low-Dose Alprazolam. <i>Journal of Neurochemistry</i> , 1987, 49, 1595-1601.	2.1	33
54	Kinetic-effect models and their applications. <i>Pharmaceutical Research</i> , 1987, 04, 86-91.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Development of acute tolerance to bumetanide: bolus injection studies. <i>Pharmaceutical Research</i> , 1987, 04, 379-384.	1.7	11
56	Pharmacokinetics and Dynamic Effects of Diltiazem in the Isolated Guinea-Pig Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 62, 166-171.	0.0	3
57	TDM OF THEOPHYLLINE—COMPLIANCE EVALUATION. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1988, 13, 273-280.	0.7	3
58	Acute barbiturate administration increases benzodiazepine receptor binding in vivo. <i>Psychopharmacology</i> , 1988, 96, 385-390.	1.5	24
59	Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring. <i>European Journal of Clinical Pharmacology</i> , 1988, 34, 395-400.	0.8	10
60	Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 203-228.	0.6	28
61	Dose and concentration-effect relations for rilmenidine. <i>American Journal of Cardiology</i> , 1988, 61, D60-D66.	0.7	21
62	Clinical pharmacokinetics of isradipine. <i>American Journal of Medicine</i> , 1988, 84, 80-89.	0.6	30
63	Effects of pinacidil on guinea-pig airway smooth muscle contracted by asthma mediators. <i>European Journal of Pharmacology</i> , 1988, 157, 221-226.	1.7	37
64	Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement. <i>Brain Research</i> , 1988, 446, 314-320.	1.1	44
65	Cortisol suppression per nanogram per milliliter of plasma dexamethasone in depressive and normal subjects. <i>Biological Psychiatry</i> , 1988, 24, 569-577.	0.7	16
66	Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: An overview. , 1988, 38, 1-52.		83
67	Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function.. <i>British Journal of Clinical Pharmacology</i> , 1988, 25, 367-373.	1.1	4
68	Concentration—effect relationships for oxprenolol in patients with essential hypertension.. <i>British Journal of Clinical Pharmacology</i> , 1988, 25, 539-545.	1.1	2
69	Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam.. <i>British Journal of Clinical Pharmacology</i> , 1988, 25, 561-569.	1.1	63
70	Ketanserin concentration—effect relationships in individual hypertensive patients.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 61-64.	1.1	8
71	Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 429-434.	1.1	32
72	Hormesis, gompertz functions, and risk assessment. <i>Drug Metabolism Reviews</i> , 1988, 19, 195-229.	1.5	35

#	ARTICLE	IF	CITATIONS
73	The Efficacy of Rifampicin against Staphylococcus aureus in Vitro and in an Experimental Infection in Normal and Granulocytopenic Mice. Scandinavian Journal of Infectious Diseases, 1988, 20, 649-656.	1.5	6
74	Basic Concepts in Pharmacodynamic Modeling. Journal of Clinical Pharmacology, 1988, 28, 388-394.	1.0	37
75	Pharmacokinetics and Blood Pressure Effects of Felodipine in Elderly Hypertensive Patients. Clinical Pharmacokinetics, 1988, 14, 374-383.	1.6	47
76	Nifedipine: individual responses and concentration-effect relationships.. Hypertension, 1988, 12, 443-449.	1.3	54
77	A kinetic study of chlorpromazine on the hyperglycemic response in rats. I. Effect of chlorpromazine on plasma catecholamines.. Journal of Pharmacobio-dynamics, 1988, 11, 486-491.	0.5	5
78	A kinetic study of chlorpromazine on the hyperglycemic response in rats. II. Effect of chlorpromazine on plasma glucose.. Journal of Pharmacobio-dynamics, 1988, 11, 492-503.	0.5	9
79	Issues on the Robust Design of Experiments for the Estimation of Nonlinear Parameters. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1988, 21, 93-97.	0.4	0
80	Population Pharmacokinetics. Journal of Clinical Pharmacology, 1988, 28, 1059-1063.	1.0	38
81	Transdermal Fentanyl: Pharmacokinetics and Preliminary Clinical Evaluation. Pharmacotherapy, 1989, 9, 2-9.	1.2	106
82	Comparison of in Vivo and in Vitro Activities of Antibiotics with Different Modes of Action against a Tolerant and a Non-tolerant Staphylococcus aureus Strain. Scandinavian Journal of Infectious Diseases, 1989, 21, 95-101.	1.5	7
83	Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: Relationship of pharmacokinetics and pharmacodynamics. Journal of Pharmacokinetics and Pharmacodynamics, 1989, 17, 551-570.	0.6	7
84	Clockwise hysteresis or proteresis. Journal of Pharmacokinetics and Pharmacodynamics, 1989, 17, 401-402.	0.6	26
85	Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. European Journal of Drug Metabolism and Pharmacokinetics, 1989, 14, 145-151.	0.6	15
86	Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses. Cardiovascular Drugs and Therapy, 1989, 3, 417-425.	1.3	10
87	Use of the median EEG frequency and pharmacokinetics in determining depth of anaesthesia. Bailliere's Clinical Anaesthesiology, 1989, 3, 603-621.	0.2	12
88	Relationship between receptor occupancy at 37 degrees C and the anticonvulsant effect of flunitrazepam in rats. Pharmaceutical Research, 1989, 06, 585-591.	1.7	6
89	A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. Pharmaceutical Research, 1989, 06, 702-705.	1.7	9
90	Racial differences in drug response: isoproterenol effects on heart rate in healthy males. Pharmaceutical Research, 1989, 06, 182-185.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Effect of bumetanide on tubuloglomerular feedback in <i>Necturus maculosus</i> . <i>Acta Physiologica Scandinavica</i> , 1989, 137, 93-99.	2.3	5
92	Pinacidil Uptake and Effects in the Isolated Rabbit Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989, 64, 14-19.	0.0	7
93	Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 579-582.	0.8	3
94	Current models in pharmacokinetics: Applications in veterinary pharmacology. <i>Veterinary Research Communications</i> , 1989, 13, 141-157.	0.6	6
95	Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 369-374.	0.8	5
96	Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. <i>Kidney International</i> , 1989, 36, 1119-1124.	2.6	42
97	A comparison of the relaxant effects of pinacidil in guinea-pig trachea, aorta and pulmonary artery. <i>European Journal of Pharmacology</i> , 1989, 167, 275-280.	1.7	18
98	Behavioural tolerance to morphine analgesia is supraspinally mediated: a quantitative analysis of dose-response relationships. <i>Brain Research</i> , 1989, 491, 316-327.	1.1	28
99	Reversible hearing impairment related to quinine blood concentrations in guinea pigs. <i>Life Sciences</i> , 1989, 45, 751-755.	2.0	21
100	Concentration-effect relationships and individual responses to doxazosin in essential hypertension.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 517-526.	1.1	28
101	Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and High-Infection Models. <i>Journal of Infectious Diseases</i> , 1989, 159, 281-292.	1.9	357
102	The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling Site. <i>Clinical Pharmacokinetics</i> , 1989, 17, 175-199.	1.6	205
103	Pharmacokinetic-Pharmacodynamic Relationships of α -Adrenoceptor Antagonists. <i>Clinical Pharmacokinetics</i> , 1989, 17, 264-274.	1.6	18
104	The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling Site. <i>Clinical Pharmacokinetics</i> , 1989, 17, 275-290.	1.6	99
105	Acute Antidepressant Effect Following Pulse Loading With Intravenous and Oral Clomipramine. <i>Archives of General Psychiatry</i> , 1989, 46, 29.	13.8	72
106	Acute and Steady-State Pharmacokinetics and Antihypertensive Effects of Felodipine in Patients with Normal and Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 1020-1030.	1.0	18
107	The Relationship Between Metoprolol Plasma Concentration and Beta ₁ -Blockade in Healthy Subjects: A Study on Conventional Metoprolol and Metoprolol CR/ZOK Formulations. <i>Journal of Clinical Pharmacology</i> , 1990, 30, S46-54.	1.0	47
108	Pulmonary Function in the Elderly: Response to Theophylline Bronchodilation. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 330-335.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Myocardial Accumulation Kinetics and Pharmacodynamics in the Isolated Rabbit Heart of a New Inhibitor of Dopamine Reuptake, GBR 12909. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 197-202.	0.0	1
110	Myocardial Effects of Adrenaline, Isoprenaline and Dobutamine at Hypothermic Conditions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 354-360.	0.0	22
111	Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 459-481.	0.6	36
112	Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines I: Lorazepam. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 89-102.	0.6	37
113	Factors influencing the responses to calcium antagonists in elderly patients with hypertension and ischaemic heart disease. <i>Experimental Gerontology</i> , 1990, 25, 375-381.	1.2	9
114	Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. <i>Pharmaceutical Research</i> , 1990, 07, 570-576.	1.7	13
115	Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. <i>Pharmaceutical Research</i> , 1990, 07, 476-483.	1.7	38
116	The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine. <i>Pharmaceutical Research</i> , 1990, 07, 96-102.	1.7	12
117	The use of kinetic-dynamic interactions in the evaluation of drugs. <i>Psychopharmacology</i> , 1990, 100, 433-450.	1.5	53
118	Dose adjustment of nifedipine in hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 1990, 38, 17-20.	0.8	7
119	The short-duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism. <i>Annals of Neurology</i> , 1990, 27, 660-665.	2.8	21
120	Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. <i>Epilepsy Research</i> , 1990, 5, 185-191.	0.8	6
121	Concentration-effect analysis of antihypertensive drug responses.. <i>Hypertension</i> , 1990, 16, 12-18.	1.3	30
122	Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 665-671.	1.0	98
123	Kinetic-dynamic relations and individual responses to enalapril.. <i>Hypertension</i> , 1990, 15, 301-309.	1.3	61
124	Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 1869-1874.	1.4	67
125	Pharmacodynamics of Antibiotics-Consequences for Dosing: Proceedings of a Symposium Held in Stockholm, June 7-9, 1990. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 1-284.	1.5	9
126	Antibacterial Activity of Four Cephalosporins in an Experimental Infection in Relation to In Vitro Effect and Pharmacokinetics. <i>Journal of Infectious Diseases</i> , 1990, 162, 717-722.	1.9	30

#	ARTICLE	IF	CITATIONS
127	Clinical Pharmacokinetics 1990. Clinical Pharmacokinetics, 1990, 18, 1-19.	1.6	10
128	Toxicokinetic-toxicodynamic models describing the relation of plasma and red blood cell potassium with plasma digitalis in acute human digitalis poisoning. Toxicology in Vitro, 1990, 4, 526-531.	1.1	3
129	Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. Journal of Allergy and Clinical Immunology, 1990, 85, 540-547.	1.5	158
130	Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery. Journal of Controlled Release, 1990, 11, 343-356.	4.8	32
131	The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives*. Fundamental and Clinical Pharmacology, 1990, 4, 103s-115s.	1.0	4
132	Do we need highly sensitive analytical techniques in phase I?. Fundamental and Clinical Pharmacology, 1990, 4, 135s-140s.	1.0	0
133	Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. American Journal of Medicine, 1990, 88, S18-S24.	0.6	43
134	Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. British Journal of Pharmacology, 1990, 99, 53-58.	2.7	13
135	Diuretic effect and diuretic efficiency after intravenous dosage of frusemide [see comments]. British Journal of Clinical Pharmacology, 1990, 29, 215-219.	1.1	30
136	Use of Emax model in diuretic studies [letter; comment]. British Journal of Clinical Pharmacology, 1990, 30, 907-908.	1.1	3
137	Do serum dexamethasone levels improve the DST?. Journal of Affective Disorders, 1990, 20, 13-18.	2.0	2
138	Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.. British Journal of Clinical Pharmacology, 1991, 31, 1-13.	1.1	30
139	Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam.. British Journal of Clinical Pharmacology, 1991, 31, 89-92.	1.1	33
140	1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.. British Journal of Clinical Pharmacology, 1991, 32, 238-241.	1.1	7
141	The influence of co-administered organic acids on the kinetics and dynamics of frusemide.. British Journal of Clinical Pharmacology, 1991, 32, 489-493.	1.1	9
142	The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of diltiazem.. British Journal of Clinical Pharmacology, 1991, 32, 591-597.	1.1	9
143	Hearing impairment related to plasma quinine concentration in healthy volunteers.. British Journal of Clinical Pharmacology, 1991, 31, 409-412.	1.1	29
144	The description and prediction of antihypertensive drug response: an individualised approach.. British Journal of Clinical Pharmacology, 1991, 31, 627-634.	1.1	12

#	ARTICLE	IF	CITATIONS
145	Physiological Changes Due to Age. <i>Drugs and Aging</i> , 1991, 1, 467-476.	1.3	6
146	Clinical Pharmacokinetics and Kinetic-Dynamic Relationships of Dilevalol and Labetalol. <i>Clinical Pharmacokinetics</i> , 1991, 21, 95-109.	1.6	15
147	Intragastric pH and Pharmacokinetics of Intravenous Ranitidine During Sinusoidal and Constant-Rate Infusions. <i>Chronobiology International</i> , 1991, 8, 267-276.	0.9	9
148	The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro. <i>Biochemical Pharmacology</i> , 1991, 42, 1729-1737.	2.0	12
149	Evidence for opiate tolerance in newborn rats. <i>Developmental Brain Research</i> , 1991, 60, 99-102.	2.1	25
150	Chronotherapeutics.. <i>Annals of the New York Academy of Sciences</i> , 1991, 618, 116-122.	1.8	3
151	Clinical Pharmacokinetics of Famotidine. <i>Clinical Pharmacokinetics</i> , 1991, 21, 178-194.	1.6	71
152	Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 1413-1422.	1.4	89
153	Pharmacokinetic Optimisation of Histamine H1-Receptor Antagonist Therapy. <i>Clinical Pharmacokinetics</i> , 1991, 21, 372-393.	1.6	49
154	Effect of Alpha-Chloralose on Disposition and Pharmacological Action of Orally Administered Chlorzoxazone in Rats.. <i>Journal of Pharmacobio-dynamics</i> , 1991, 14, 429-434.	0.5	2
155	Concentration-effect relations of 5-hydroxypropafenone in normal subjects. <i>American Journal of Cardiology</i> , 1991, 67, 1022-1026.	0.7	8
156	Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203â€“922. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 287-309.	0.6	16
157	Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 123-143.	0.6	41
158	A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 537-552.	0.6	58
159	Drug metabolism and interactions in abuse liability assessment. <i>Addiction</i> , 1991, 86, 1607-1614.	1.7	7
160	Modelâ€“based adaptive closedâ€“loop feedback control of atracuriumâ€“induced neuromuscular blockade. <i>Acta Anaesthesiologica Scandinavica</i> , 1991, 35, 420-423.	0.7	30
161	Relationship between Red Blood Cell Potassium and Plasma Digitoxin Concentrations in Intoxicated Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 68, 237-242.	0.0	2
162	A System Approach to Pharmacodynamics. III: An Algorithm and Computer Program, COLAPS, for Pharmacodynamic Modeling. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 488-495.	1.6	26

#	ARTICLE	IF	CITATIONS
163	Relationship between Skin Fluorescence and Blood Flow in Normal and in Chronically Ischemic Subjects Dosed with Fluorescein. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 632-637.	1.6	2
164	Biophase Equilibration Times. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 881-886.	1.6	7
165	Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. <i>Psychopharmacology</i> , 1991, 103, 46-49.	1.5	6
166	Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. <i>Psychopharmacology</i> , 1991, 103, 443-448.	1.5	37
167	A simulation study comparing designs for dose ranging. <i>Statistics in Medicine</i> , 1991, 10, 303-321.	0.8	101
168	Acute haemodynamic effects of i.v. nitrendipine in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 99-103.	0.8	4
169	Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 165-9.	0.8	25
170	Effect of Basal Gastric Acid Secretion on the Pharmacodynamics of Ranitidine. <i>Chronobiology International</i> , 1991, 8, 186-193.	0.9	5
172	Dose-Dependent Effects of Betaxolol in Hypertension: A Double-Blind, Multicenter Study. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 360-367.	1.0	3
173	Dosage Regimen Design: Pharmacodynamic Considerations. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 597-602.	1.0	9
174	Dosage Regimen Design: A Pharmacokinetic Approach. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 210-214.	1.0	1
175	Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 11466-11470.	3.3	87
176	Clinical Pharmacokinetics in Veterinary Medicine. <i>Clinical Pharmacokinetics</i> , 1992, 22, 254-273.	1.6	49
177	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 942-948.	1.4	140
178	Quantification of Theophylline-Induced Eosinopenia and Hypokalaemia in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 1992, 22, 231-237.	1.6	8
179	Pharmacokinetics of Factor VIII in Humans. <i>Clinical Pharmacokinetics</i> , 1992, 22, 385-395.	1.6	45
180	Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 47-52.	1.1	23
181	Effect of age on ibuprofen pharmacokinetics and antipyretic response. <i>Journal of Pediatrics</i> , 1992, 121, 969-973.	0.9	72

#	ARTICLE	IF	CITATIONS
182	Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. <i>Journal of Pediatrics</i> , 1992, 121, 974-980.	0.9	38
183	Antihypertensive drugs: Individualized analysis and clinical relevance of kinetic-dynamic relationships. <i>Journal of Clinical Pharmacology</i> , 1992, 53, 67-79.		12
184	Clinical Pharmacokinetics of Calcium Antagonists. <i>Clinical Pharmacokinetics</i> , 1992, 22, 416-433.	1.6	102
185	Statistical Issues Arising in AIDS Clinical Trials: Rejoinder. <i>Journal of the American Statistical Association</i> , 1992, 87, 581.	1.8	0
186	Effects of amiloride analogues on AVP binding and activation of V1-receptor-expressing cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1992, 262, E76-E86.	1.8	5
187	Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 337-340.	0.8	10
188	BIOEQUIVALENCE OF TOPICAL CORTICOSTEROIDS: A REGULATORY PERSPECTIVE. <i>International Journal of Dermatology</i> , 1992, 31, 2-5.	0.5	8
189	Comparative anticonvulsant potency and pharmacokinetics of (+)- and (âˆ™)-enantiomers of stiripentol. <i>Epilepsy Research</i> , 1992, 12, 29-36.	0.8	33
190	Quantification of metoprolol Beta2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. <i>Pulmonary Pharmacology</i> , 1992, 5, 31-38.	0.5	11
191	Salbutamol disposition and dynamics in conscious rabbits: Influence of the route of administration and of the dose. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 461-476.	0.6	8
192	Application of semilinear canonical correlation to the measurement of opioid drug effect. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 611-635.	0.6	27
193	Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. <i>Pharmaceutical Research</i> , 1992, 09, 291-297.	1.7	26
194	Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. <i>Psychopharmacology</i> , 1992, 106, S46-S48.	1.5	25
195	Nicotine elimination and tolerance in non-dependent cigarette smokers. <i>Psychopharmacology</i> , 1992, 109, 449-456.	1.5	64
196	Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 51-55.	0.8	18
197	Quantification of tissue distribution of antibiotics by kinetic hysteresis analysis. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 517-522.	0.8	1
198	Interaction between succinylcholine and cimetidine in rats. <i>Canadian Journal of Anaesthesia</i> , 1992, 39, 370-374.	0.7	6
199	Isradipine Dynamics and Pharmacokinetics in the Isolated Rabbit Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992, 70, 366-372.	0.0	3

#	ARTICLE	IF	CITATIONS
200	Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: In vitro inhibition of human platelet cyclooxygenase activity. <i>Chirality</i> , 1992, 4, 484-487.	1.3	63
201	Rapid chiral separation of metoprolol in plasma-application to the pharmacokinetics/pharmacodynamics of metoprolol enantiomers in the conscious goat. <i>Biomedical Chromatography</i> , 1992, 6, 99-105.	0.8	8
202	Pharmacokinetics/pharmacodynamics of labetalol in three pregnant ewes using high-performance liquid chromatography. <i>Biopharmaceutics and Drug Disposition</i> , 1992, 13, 375-381.	1.1	0
203	The effects of chronic oral diltiazem and cimetidine dosing on the pharmacokinetics and negative dromotropic action of intravenous and oral diltiazem in the dog. <i>Biopharmaceutics and Drug Disposition</i> , 1992, 13, 521-537.	1.1	8
204	Stereochemical Considerations in Pharmacodynamic Modeling of Chiral Drugs. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 199-200.	1.6	13
205	Pharmacokinetic-Pharmacodynamic Modeling: Time-Dependent Protein Binding—An Alternative Interpretation of Clockwise and Counterclockwise Hysteresis. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 232-236.	1.6	12
206	Pharmacokinetics and pharmacodynamics in the design of controlled-release beads with acetaminophen as model drug. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 444-448.	1.6	15
207	Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase isozymes by repeated cyanamide administration: Pharmacokinetic-pharmacodynamic relationships. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 419-428.	1.1	1
208	A new model to assess analgesic activity: Pain-induced functional impairment in the rat (PIFIR). <i>Drug Development Research</i> , 1993, 28, 169-175.	1.4	65
209	Population Pharmacodynamic Modeling of Drug-Induced Anemia. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 546-549.	1.6	4
210	Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 177-182.	0.8	6
211	Pharmacodynamic modeling of the antihypertensive response to amlodipine. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 303-310.	2.3	40
212	SUFENTANIL AND ALFENTANIL CAUSE VASORELAXATION BY MECHANISMS INDEPENDENT OF THE ENDOTHELIUM. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1993, 20, 705-711.	0.9	11
213	Pharmacokinetics and Dynamic Response of Plain and Slow Release Isradipine Formulations in Moderately Hypertensive Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 73, 279-284.	0.0	7
214	Dynamic Effects and Pharmacokinetics of Lemakalim in the Isolated Guinea Pig Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 73, 96-102.	0.0	1
215	Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal. <i>Pharmaceutical Research</i> , 1993, 10, 136-140.	1.7	18
216	A mathematical model for dynamics of cardiovascular drug action: Application to intravenous dihydropyridines in healthy volunteers. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 489-514.	0.6	38
217	Comparison of four basic models of indirect pharmacodynamic responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 457-478.	0.6	699

#	ARTICLE	IF	CITATIONS
218	Effect modelling for drugs undergoing enterohepatic circulation. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1993, 18, 333-338.	0.6	7
219	Pharmacokinetic-pharmacodynamic relationships in Phase I/Phase II of drug development. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1993, 18, 49-59.	0.6	17
220	Interaction between succinylcholine and ranitidine in rats. <i>Canadian Journal of Anaesthesia</i> , 1993, 40, 32-37.	0.7	10
221	Comparative pharmacodynamics of CYP2B induction by phenobarbital in the male and female F344/NCr rat. <i>Biochemical Pharmacology</i> , 1993, 45, 521-526.	2.0	15
222	Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 1-9.	1.1	11
223	Importance of Early Blood Sampling on Vecuronium Pharmacokinetic and Pharmacodynamic Parameters. <i>Clinical Pharmacokinetics</i> , 1993, 24, 507-518.	1.6	50
224	Theophylline Target Concentration in Severe Airways Obstruction - 10 or 20 mg/L?. <i>Clinical Pharmacokinetics</i> , 1993, 25, 495-505.	1.6	52
225	Time and Theophylline Concentration Help Explain the Recovery of Peak Flow Following Acute Airways Obstruction. <i>Clinical Pharmacokinetics</i> , 1993, 25, 506-515.	1.6	34
226	Dose-response relationships for the induction of P450 2B by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in rat and cultured rat hepatocytes. <i>Xenobiotica</i> , 1993, 23, 1411-1426.	0.5	19
227	Data-derived safety factors for the evaluation of food additives and environmental contaminants. <i>Food Additives and Contaminants</i> , 1993, 10, 275-305.	2.0	270
228	Receptor-Based Pharmacokinetic-Pharmacodynamic Analysis of Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 115-123.	1.0	120
229	Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. <i>Xenobiotica</i> , 1993, 23, 575-588.	0.5	10
230	Activity of Erythromycin and Clindamycin in an Experimental <i>Staphylococcus aureus</i> Infection in Normal and Granulocytopenic Mice. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 123-132.	1.5	6
231	Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. <i>Journal of Psychopharmacology</i> , 1993, 7, 24-32.	2.0	15
232	PHARMACODYNAMICS OF MIVACURIUM IN CHILDREN, USING A COMPUTER-CONTROLLED INFUSION. <i>British Journal of Anaesthesia</i> , 1993, 71, 232-237.	1.5	26
233	Labetalol in Hypertension During the Third Trimester of Pregnancy: Its Antihypertensive Effect and Pharmacokinetic-Dynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 979-988.	1.0	27
234	Aldose Reductase Inhibitory and Uricosuric Activities of FK366 in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 1122-1131.	1.0	7
235	Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.. <i>Journal of Clinical Oncology</i> , 1993, 11, 2010-2020.	0.8	182

#	ARTICLE	IF	CITATIONS
236	Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 1993, 11, 1179-1188.	0.8	44
237	Circadian Activity of Topical 0.05% Betamethasone Dipropionate in Human Skin In Vivo. Journal of Investigative Dermatology, 1994, 102, 734-739.	0.3	33
238	Foscarnet for suppression of human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy, 1994, 38, 604-607.	1.4	34
239	Relationship Between Plasma Concentrations Of 3'-Deoxy-3'-Fluorothymidine (Alovedine) And Antiretroviral Activity In Two Concentration-Controlled Trials. Journal of Infectious Diseases, 1994, 170, 1394-1403.	1.9	77
240	Pharmacokinetic and pharmacodynamic models of antimicrobial drugs In vitro and In vivo. Infection, 1994, 22, 377-378.	2.3	2
241	Development of acute tolerance after oral doses of diazepam and flunitrazepam. Psychopharmacology, 1994, 113, 304-310.	1.5	9
242	Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolapagrel, a novel inhibitor of thromboxane synthase, in normal volunteers. European Journal of Clinical Pharmacology, 1994, 47, 275-280.	0.8	3
243	The effect of ciclopropium on human heart rate. European Journal of Clinical Pharmacology, 1994, 46, 455-9.	0.8	0
244	A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Statistics in Medicine, 1994, 13, 2289-2309.	0.8	61
245	Implications of chirality on pharmacodynamic modeling. Chirality, 1994, 6, 467-471.	1.3	2
246	Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. International Journal of Cancer, 1994, 59, 83-93.	2.3	42
247	Hepatic cytochrome P450 2B induction by ethyl/ phenyl-substituted congeners of phenobarbital in the B6C3F1 mouse. Journal of Biochemical Toxicology, 1994, 9, 269-278.	0.5	4
248	Absence of enantioselectivity in the pharmacodynamics of P450 2B induction by 5-ethyl-5-phenylhydantoin in the male rat liver or in cultured rat hepatocytes. Journal of Biochemical Toxicology, 1994, 9, 279-288.	0.5	10
249	Quantitative evaluation of an experimental inflammation induced with Freund's Complete Adjuvant in dogs. Journal of Pharmacological and Toxicological Methods, 1994, 32, 63-71.	0.3	19
250	The use of multiple doses and pharmacodynamic system analysis to distinguish between dispositional delays and time-variant pharmacodynamics. Pharmaceutical Research, 1994, 11, 1825-1828.	1.7	2
251	Effect of the H2-receptor antagonist cimetidine, on the pharmacokinetics and pharmacodynamics of the H1-receptor antagonists hydroxyzine and cetirizine in rabbits. Pharmaceutical Research, 1994, 11, 295-300.	1.7	4
252	The effect of thiopental on cerebral blood flow, and its relation to plasma concentration, during simulated induction of anaesthesia in a porcine model. Acta Anaesthesiologica Scandinavica, 1994, 38, 473-478.	0.7	7
253	Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. Journal of Veterinary Pharmacology and Therapeutics, 1994, 17, 459-469.	0.6	93

#	ARTICLE	IF	CITATIONS
254	Biotechnology Products. Handbook of Experimental Pharmacology, 1994, , 355-370.	0.9	0
256	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 34, 103-108.	1.1	9
257	Metabolism of 3-azido-2-deoxythymidine (AZT) in human placentae trophoblasts and Hofbauer cells. Biochemical Pharmacology, 1994, 48, 383-389.	2.0	50
258	Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.. British Journal of Clinical Pharmacology, 1994, 37, 553-557.	1.1	12
259	Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children [see comments]. British Journal of Clinical Pharmacology, 1994, 38, 71-76.	1.1	56
260	Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. British Journal of Pharmacology, 1994, 113, 317-323.	2.7	7
261	Effect of temperature on opioid dependence and on the abstinence response in the isolated guinea pig ileum. Life Sciences, 1994, 56, 465-474.	2.0	1
262	Vecuronium Pharmacokinetic-Pharmacodynamic Modelling With and Without a Receptor Concentration in the Effect Compartment in Anaesthetised Patients. Drug Investigation, 1994, 7, 74-83.	0.6	7
263	Influence of Drug Formulation on Drug Concentration-Effect Relationships. Clinical Pharmacokinetics, 1994, 26, 135-143.	1.6	26
264	Concentration-Effect Analysis of Antihypertensive Drug Response. Clinical Pharmacokinetics, 1994, 26, 472-485.	1.6	12
265	Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertility and Sterility, 1994, 61, 687-695.	0.5	73
266	Invasive Pharmacodynamics of Fosinopril in Patients with Congestive Heart Failure. Journal of Clinical Pharmacology, 1995, 35, 785-793.	1.0	4
267	Immunopharmacodynamic Studies of Cyclosporine in Patients Awaiting Renal Transplantation. Journal of Clinical Pharmacology, 1995, 35, 967-973.	1.0	5
268	The Pharmacokinetics and Cardiovascular Pharmacodynamics of HP 749 (Besipirdine HCl) and Metabolite P867480 in the Conscious Monkey. Journal of Clinical Pharmacology, 1995, 35, 688-696.	1.0	2
269	Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. Journal of Veterinary Pharmacology and Therapeutics, 1995, 18, 315-324.	0.6	85
270	Resistance to atracurium in rats with experimental inflammation: role of protein binding. Acta Anaesthesiologica Scandinavica, 1995, 39, 1019-1023.	0.7	14
271	Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. Chirality, 1995, 7, 586-597.	1.3	56
272	The influence of food intake on the effect of two controlled release formulations of furosemide. Biopharmaceutics and Drug Disposition, 1995, 16, 221-232.	1.1	16

#	ARTICLE	IF	CITATIONS
273	Effects of renal function on recainam pharmacokinetics and pharmacodynamics*. Clinical Pharmacology and Therapeutics, 1995, 57, 492-498.	2.3	0
274	Felodipine population dose-response and concentration-response relationships in patients with essential hypertension*. Clinical Pharmacology and Therapeutics, 1995, 57, 569-581.	2.3	26
275	Stereoselectivity in cardiovascular and biochemical action of calcium antagonists: Studies with the enantiomers of the dihydropyridine nitrendipine*. Clinical Pharmacology and Therapeutics, 1995, 57, 52-61.	2.3	11
276	Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*. Clinical Pharmacology and Therapeutics, 1995, 57, 533-542.	2.3	61
277	Pharmacodynamic modelling of the drug-induced downregulation of a β_2 -adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. European Journal of Clinical Pharmacology, 1995, 49, 37-44.	0.8	7
278	Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. European Journal of Clinical Pharmacology, 1995, 47, 483-488.	0.8	19
279	Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem. European Journal of Clinical Pharmacology, 1995, 48, 45-9.	0.8	5
280	INFLUENCE OF CONFOUNDING FACTORS ON DESIGNS FOR DOSE-EFFECT RELATIONSHIP ESTIMATES. Statistics in Medicine, 1995, 14, 987-1005.	0.8	6
281	A time correlation study between reflectance spectroscopic cutaneous vasoconstriction and plasma corticosteroid concentration. British Journal of Dermatology, 1995, 132, 59-65.	1.4	4
282	A semicompartamental modeling approach for pharmacodynamic data assessment. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 307-322.	0.6	3
283	Application of multivariable feedback methods to intravenous anesthetic pharmacodynamics. , 0, , .		1
284	Drug Cytotoxicity Assay for African Trypanosomes and Leishmania Species. Journal of Infectious Diseases, 1995, 172, 1157-1159.	1.9	95
285	Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3726-3730.	3.3	159
286	Fluticasone propionate - an update on preclinical and clinical experience. Respiratory Medicine, 1995, 89, 3-18.	1.3	104
287	Antitrypanosomal activity of camptothecin analogs. Biochemical Pharmacology, 1995, 50, 937-942.	2.0	63
288	Characterization of bile salt uptake by Giardia lamblia. International Journal for Parasitology, 1995, 25, 1089-1097.	1.3	18
289	Quantitation of H1-receptor antagonists in skin and serum. Journal of Allergy and Clinical Immunology, 1995, 95, 759-764.	1.5	41
290	Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee.. British Journal of Clinical Pharmacology, 1995, 40, 407-410.	1.1	7

#	ARTICLE	IF	CITATIONS
291	Quinidine pharmacodynamics in patients with arrhythmia: Effects of left ventricular function. <i>Journal of the American College of Cardiology</i> , 1995, 25, 989-994.	1.2	4
292	Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines. <i>Clinical Pharmacokinetics</i> , 1995, 28, 419-432.	1.6	39
293	Chapter 13 Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. <i>Progress in Brain Research</i> , 1995, 106, 123-134.	0.9	60
294	Population Pharmacokinetics: Fundamentals, Methods and Applications. <i>Drug Development and Industrial Pharmacy</i> , 1995, 21, 1115-1141.	0.9	11
295	Concentration-Effect Relationship of Levodopa in Patients with Parkinson's Disease. <i>Clinical Pharmacokinetics</i> , 1995, 29, 243-256.	1.6	39
296	Pharmacokinetics and Pharmacodynamics of a Second Dose of Atracurium in Anaesthetised Patients. <i>Clinical Drug Investigation</i> , 1995, 9, 98-110.	1.1	7
297	Pharmacokinetic modelling of the haemodynamic effects of the A _{2a} adenosine receptor agonist CGS 21680C in conscious normotensive rats. <i>British Journal of Pharmacology</i> , 1995, 114, 761-768.	2.7	22
298	Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children [letter; comment]. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 214-215.	1.1	26
299	Population pharmacodynamics of romazarit.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 313-320.	1.1	14
300	Practical implications of pharmacokinetic and pharmacodynamic (PK/PD) modelling of drug dose regimens. <i>Equine Veterinary Journal</i> , 1995, 27, 245-246.	0.9	0
301	Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. <i>Equine Veterinary Journal</i> , 1995, 27, 247-256.	0.9	79
302	AN APPLICATION OF BAYESIAN POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELS TO DOSE RECOMMENDATION. <i>Statistics in Medicine</i> , 1995, 14, 971-986.	0.8	54
303	Chronopharmacokinetics and Chronopharmacodynamics of Dextromethamphetamine in Man. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 1051-1063.	1.0	42
304	Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A ₁ and A _{2a} receptors <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 1996, 118, 369-377.	2.7	9
305	The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. <i>British Journal of Pharmacology</i> , 1996, 119, 885-890.	2.7	21
306	Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. <i>Research in Veterinary Science</i> , 1996, 61, 26-32.	0.9	47
307	Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 1996, 31, 103-110.	1.6	18
308	Anesthetic Potency of Remifentanil in Dogs. <i>Anesthesiology</i> , 1996, 84, 865-872..	1.3	86

#	ARTICLE	IF	CITATIONS
309	Remifentanil Versus Alfentanil. <i>Anesthesiology</i> , 1996, 84, 821-833..	1.3	399
310	Pharmacokinetic Origin of Carbamazepine-induced Resistance to Vecuronium Meeting Abstracts in Anesthetized Patients. <i>Anesthesiology</i> , 1996, 84, 330-339..	1.3	77
311	A comparison of a bayesian population method with two methods as implemented in commercially available software. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 403-432.	0.6	52
312	Loading dose imipramineâ€”New approach to pharmacotherapy of melancholic depression. <i>Journal of Psychiatric Research</i> , 1996, 30, 51-58.	1.5	22
313	Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data. <i>Pharmaceutical Research</i> , 1996, 13, 1804-1810.	1.7	9
314	Performance assessment of an adaptive model-based feedback controller: comparison between atracurium, mivacurium, rocuronium and vecuronium. <i>Journal of Clinical Monitoring and Computing</i> , 1996, 13, 217-224.	0.3	26
315	Changes in apomorphine pharmacodynamics following repeated treatment in 6-hydroxydopamine-lesioned rats. <i>Brain Research</i> , 1996, 729, 190-196.	1.1	9
316	Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia. <i>American Journal of Cardiology</i> , 1996, 78, 579-581.	0.7	2
317	Disposition and Analgesic Effects of Systemic Morphine, Morphineâ€”Glucuronide and Normorphine in Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 79, 40-46.	0.0	17
318	Pharmacokineticâ€”Pharmacodynamic Modelling of Zopiclone Effects on Human Central Nervous System. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 348-353.	0.0	4
319	Pharmacokineticâ€”pharmacodynamic model for spiramycin in staphylococcal mastitis. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1996, 19, 95-103.	0.6	12
320	The response to levodopa in parkinson's disease: Imposing pharmacological law and order. <i>Annals of Neurology</i> , 1996, 39, 561-573.	2.8	296
321	Modelling based method for pharmacokinetic hypotheses test. <i>Acta Biotheoretica</i> , 1996, 44, 335-348.	0.7	4
322	Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1996, 49, 279-284.	0.8	0
323	Pharmacologic Properties of Ketorolac Tromethamine: A Potent Analgesic Drug. <i>CNS Neuroscience & Therapeutics</i> , 1996, 2, 75-90.	4.0	14
324	The implications of nonâ€”linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 605-613.	1.1	8
325	An Integrated Pharmacokinetic and Pharmacodynamic Approach to Controlled Drug Delivery. <i>Journal of Drug Targeting</i> , 1996, 3, 411-415.	2.1	9
326	Pharmacokinetics and Pharmacodynamics of Famotidine in Children. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 48-54.	1.0	28

#	ARTICLE	IF	CITATIONS
327	Synergy Between Deltamethrin and Prochloraz in Bees: Different Mechanisms of Action Tested by Modeling. SAR and QSAR in Environmental Research, 1996, 5, 185-211.	1.0	3
329	Exploratory and Population Pharmacodynamic Analysis of Pilot Dose-Response Data in the Bioequivalence Testing of Topical Corticosteroid Preparations. Drug Information Journal, 1997, 31, 1215-1226.	0.5	0
330	A Pharmacokinetic-Pharmacodynamic Model of β -Sotalolol Q ₁₀ Prolongation During Intravenous Administration to Healthy Subjects. Journal of Clinical Pharmacology, 1997, 37, 799-809.	1.0	20
331	The use of the plasma concentration-effect relationship as a tool for the study of the mechanism of action of naloxone effects on mood and endocrine function. Journal of Psychopharmacology, 1997, 11, 361-365.	2.0	8
332	The Correlation Between Pharmacodynamics and Pharmacokinetics: Basics of Pharmacokinetics-Pharmacodynamics Modeling. Journal of Clinical Pharmacology, 1997, 37, 65S-69S.	1.0	5
333	The Comparative Amnestic Effects of Midazolam, Propofol, Thiopental, and Fentanyl at Equisedative Concentrations. Anesthesiology, 1997, 87, 749-764.	1.3	196
334	Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. Clinical Pharmacokinetics, 1997, 32, 145-172.	1.6	11
335	Examples of in Vitro-in Vivo Relationships with a Diverse Range of Quality. Advances in Experimental Medicine and Biology, 1997, 423, 1-15.	0.8	5
337	Nocifensive reflex thresholds in rats: measures of central nervous system effects of barbiturates. Canadian Journal of Anaesthesia, 1997, 44, 765-774.	0.7	10
338	The effect of nigral implantation on sensitization to dopamine agonists in 6-hydroxydopamine-lesioned rats. Neuroscience, 1997, 79, 963-972.	1.1	1
339	Relationship of Muscle Strength to Potassium Concentration in a Hypokalaemic Infant. Anaesthesia and Intensive Care, 1997, 25, 525-527.	0.2	3
340	Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrobial Agents and Chemotherapy, 1997, 41, 449-453.	1.4	18
341	Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.. Journal of Clinical Oncology, 1997, 15, 1087-1093.	0.8	63
342	Concentration-Effect Relationship after Intravenous Hydromorphone Administration: Use of An Effect Compartment Model and System Analysis to Minimize Hysteresis of Effects. Pain Research and Management, 1997, 2, 167-172.	0.7	0
343	Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass. Brazilian Journal of Medical and Biological Research, 1997, 30, 369-374.	0.7	7
344	The effect of α -adrenergic antagonism upon nitrogen loss during endotoxemia. Nutrition, 1997, 13, 887-894.	1.1	3
345	Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate. Journal of Pharmacokinetics and Pharmacodynamics, 1997, 25, 23-37.	0.6	11
346	The pharmacokinetics and electroencephalogram response of remifentanyl alone and in combination with esmolol in the rat. Pharmaceutical Research, 1997, 14, 1817-1823.	1.7	16

#	ARTICLE	IF	CITATIONS
347	Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 202-208.	1.1	1
348	Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. <i>European Journal of Clinical Pharmacology</i> , 1997, 53, 221-228.	0.8	21
349	The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 35-44.	2.3	24
350	Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 552-560.	2.3	84
351	Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 302-311.	2.3	31
352	Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium. <i>Journal of Clinical Monitoring and Computing</i> , 1998, 14, 329-337.	0.7	4
353	Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. <i>Pharmaceutical Research</i> , 1998, 15, 4-7.	1.7	5
354	Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. , 1998, 15, 1063-1068.		3
355	Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. <i>Pharmaceutical Research</i> , 1998, 15, 466-473.	1.7	65
356	Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 717-733.	0.6	8
357	Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 547-557.	0.8	22
358	Estimating potency for the Emax-model without attaining maximal effects. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 581-593.	0.8	47
359	Myocardial Effect Compartment Modeling of Metoprolol and Sotalol: Importance of Myocardial Subsite Drug Concentration. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 177-182.	1.6	9
360	Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy. <i>British Journal of Pharmacology</i> , 1998, 125, 615-620.	2.7	12
361	Amlodipine Dynamic Effects and Myocardial Pharmacokinetics in the Isolated and Perfused Guineaâ€Pig Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998, 82, 250-256.	0.0	5
362	An integrated pharmacokineticâ€pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease. <i>Advanced Drug Delivery Reviews</i> , 1998, 33, 253-263.	6.6	19
363	Effects of repeated seizure induction on seizure activity, post-ictal and interictal behavior. <i>Brain Research</i> , 1998, 814, 199-208.	1.1	7
364	40 Hz Auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. <i>Canadian Journal of Anaesthesia</i> , 1998, 45, 115-121.	0.7	23

#	ARTICLE	IF	CITATIONS
365	Pharmacokinetic-pharmacodynamic modeling of pentazocine under general anesthesia â€”Effect of infusion period on respiratory rateâ€”. <i>Odontology</i> , 1998, 86, 54-63.	0.1	0
366	What we donâ€™t know about paracetamol in children. <i>Paediatric Anaesthesia</i> , 1998, 8, 451-460.	0.6	65
367	The time of maximum effect for model selection in pharmacokineticâ€” pharmacodynamic analysis applied to frusemide. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 63-70.	1.1	24
368	Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 229-239.	1.1	178
369	Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 237-243.	1.1	87
370	Expanding clinical applications of population pharmacodynamic modelling. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 321-333.	1.1	54
371	A radioreceptor assay for the analysis of AT1-receptor antagonists. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 111-124.	1.4	13
372	Pharmacokineticâ€”pharmacodynamic modelling of behavioural responses. <i>Neuroscience and Biobehavioral Reviews</i> , 1998, 23, 229-236.	2.9	11
373	Revisiting the effect compartment through timing errors in drug administration. <i>Trends in Pharmacological Sciences</i> , 1998, 19, 49-54.	4.0	22
374	Five days of oral topotecan (hycamtinÂ®), a phase I and pharmacological study in adult patients with solid tumours. <i>European Journal of Cancer</i> , 1998, 34, 1030-1035.	1.3	50
375	COMPARATIVE PHARMACODYNAMICS OF CYP2B INDUCTION BY DDT, DDE, AND DDD IN MALE RAT LIVER AND CULTURED RAT HEPATOCYTES. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1998, 53, 455-477.	1.1	66
376	Methodological Issues in Pharmacokinetic-Pharmacodynamic Modelling. <i>Clinical Pharmacokinetics</i> , 1998, 35, 151-166.	1.6	42
377	Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. <i>Fertility and Sterility</i> , 1998, 69, 201-209.	0.5	56
378	Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone. III. Pharmacokinetic-Pharmacodynamic Modeling After Repeated Subcutaneous Administration. <i>Fertility and Sterility</i> , 1998, 69, 32S-39S.	0.5	20
379	Statistical methods for population pharmacokinetic modelling. <i>Statistical Methods in Medical Research</i> , 1998, 7, 63-84.	0.7	42
380	Pharmacokinetics and Pharmacodynamics of Growth Hormone-Releasing Peptide-2: A Phase I Study in Children¹. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1168-1172.	1.8	25
381	Pharmacokinetics and Pharmacodynamics of Bumetanide in Critically Ill Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 994-1002.	1.0	22
382	Pharmacokinetics and Pharmacodynamics of Ranitidine in Neonates Treated with Extracorporeal Membrane Oxygenation. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 402-407.	1.0	28

#	ARTICLE	IF	CITATIONS
383	The Analgesic Potency of Dexmedetomidine Is Enhanced After Nerve Injury. <i>Anesthesia and Analgesia</i> , 1998, 87, 941-948.	1.1	10
384	The Analgesic Potency of Dexmedetomidine Is Enhanced After Nerve Injury. <i>Anesthesia and Analgesia</i> , 1998, 87, 941-948.	1.1	122
385	Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. <i>Brazilian Journal of Medical and Biological Research</i> , 1998, 31, 691-696.	0.7	22
386	In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against <i>Streptococcus pneumoniae</i> : Application to Breakpoint Determinations. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2375-2379.	1.4	239
387	Induction of Hepatic Cytochromes P450 by Dietary 1,4-Bis[(3,5-dichloropyridyloxy)] benzene (TCPOBOP) in the B6C3F1 Mouse: Dose-Dependence and Pharmacodynamics. <i>International Journal of Toxicology</i> , 1999, 18, 123-130.	0.6	2
388	Effect-site modelling of propofol using auditory evoked potentials. <i>British Journal of Anaesthesia</i> , 1999, 82, 333-339.	1.5	54
389	Pharmacologic Considerations for Therapeutic Success with Antiretroviral Agents. <i>Annals of Pharmacotherapy</i> , 1999, 33, 989-995.	0.9	40
390	USING COMPUTER SIMULATIONS FOR EVALUATING THE EFFICACY OF BREAST CANCER CHEMOTHERAPY PROTOCOLS. <i>Mathematical Models and Methods in Applied Sciences</i> , 1999, 09, 599-615.	1.7	36
391	Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 63-70.	1.1	21
392	Target concentration intervention: beyond Y2K. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 9-13.	1.1	79
393	Enantiospecific pharmacokinetics and pharmacodynamics of ketoprofen in sheep. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1999, 22, 349-359.	0.6	50
394	Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 234-240.	1.6	23
395	Developmental pharmacodynamics of cyclosporine. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 66-75.	2.3	56
396	Impaired endothelial-dependent forearm vascular relaxation in black Americans. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 408-412.	2.3	46
397	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 685-694.	2.3	119
398	Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: a novel pharmacokinetic-pharmacodynamic model. <i>Pharmaceutical Research</i> , 1999, 16, 123-129.	1.7	6
399	Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. <i>Investigational New Drugs</i> , 1999, 17, 121-135.	1.2	84
400	Comparison of the Effects of Calcitonin Gene-Related Peptide and Amylin on Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1302-1309.	3.1	105

#	ARTICLE	IF	CITATIONS
401	Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 140-151.	2.3	29
402	Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 346-357.	2.3	30
403	Indirect-response modeling of desmopressin at different levels of hydration. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 513-529.	0.8	12
404	Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. <i>Psychopharmacology</i> , 1999, 144, 272-278.	1.5	29
405	A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-inflammatory drugs by caffeine. <i>Journal of Pharmacological and Toxicological Methods</i> , 1999, 42, 67-72.	0.3	30
406	Dose response studies: how do we make them conclusive?. , 1999, 18, 629-641.		25
407	Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. , 1999, 20, 101-106.		10
408	Population modelling in drug development. <i>Statistical Methods in Medical Research</i> , 1999, 8, 183-193.	0.7	72
409	A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. <i>Statistical Methods in Medical Research</i> , 1999, 8, 217-245.	0.7	22
410	Alterations in Methadone Metabolism During Late Pregnancy. <i>Journal of Addictive Diseases</i> , 1999, 18, 51-61.	0.8	68
411	DESIGN AND ANALYSIS ISSUES FOR CROSSOVER DESIGNS IN PHASE I CLINICAL STUDIES. <i>Journal of Biopharmaceutical Statistics</i> , 1999, 9, 109-128.	0.4	12
413	An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project. <i>Toxicology in Vitro</i> , 1999, 13, 549-554.	1.1	61
414	The Efficiency Concept in Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 1999, 36, 375-389.	1.6	22
415	Basis of Anti-Infective Therapy. <i>Clinical Pharmacokinetics</i> , 1999, 37, 289-304.	1.6	27
416	The clinical pharmacology of brompheniramine in children. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 223-226.	1.5	14
417	Comparison of the Effect-site keOs of Propofol for Blood Pressure and EEG Bispectral Index in Elderly and Younger Patients. <i>Anesthesiology</i> , 1999, 90, 1517-1527..	1.3	199
418	The Effects of Dexmedetomidine on Neuromuscular Blockade in Human Volunteers. <i>Anesthesia and Analgesia</i> , 1999, 88, 633-639.	1.1	23
419	Assessment of QTc Prolongation for Non-Cardiac-Related Drugs from a Drug Development Perspective. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 349-358.	1.0	37

#	ARTICLE	IF	CITATIONS
420	The Effects on Resting Ventilation of Intravenous Infusions of Morphine or Sameridine, a Novel Molecule with Both Local Anesthetic and Opioid Properties. <i>Anesthesia and Analgesia</i> , 1999, 88, 160-165.	1.1	3
421	Propofol Requirement Is Decreased in Patients with Large Supratentorial Brain Tumor. <i>Anesthesiology</i> , 1999, 90, 1571-1576..	1.3	16
422	The Effects of Dexmedetomidine on Neuromuscular Blockade in Human Volunteers. <i>Anesthesia and Analgesia</i> , 1999, 88, 633-639.	1.1	54
423	Perioperative Pharmacodynamics of Acetaminophen Analgesia in Children. <i>Anesthesiology</i> , 1999, 90, 411-421.	1.3	170
424	The Effects on Resting Ventilation of Intravenous Infusions of Morphine or Sameridine, a Novel Molecule with Both Local Anesthetic and Opioid Properties. <i>Anesthesia and Analgesia</i> , 1999, 88, 160-165.	1.1	10
425	Determination of the Potency of Remifentanyl Compared with Alfentanil Using Ventilatory Depression as the Measure of Opioid Effect. <i>Anesthesiology</i> , 1999, 90, 1556-1563..	1.3	74
426	Temperature-dependent Pharmacokinetics and Pharmacodynamics of Vecuronium. <i>Anesthesiology</i> , 2000, 92, 84-84.	1.3	119
427	Postcesarean Epidural Morphine: A Dose-Response Study. <i>Anesthesia and Analgesia</i> , 2000, 90, 887-891.	1.1	96
428	Aging Is Associated with Endothelial Dysfunction in the Human Forearm Vasculature. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 193-198.	1.3	61
429	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	1.0	20
430	Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model. <i>Journal of Biomedical Informatics</i> , 2000, 33, 211-226.	0.7	75
431	The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. <i>Movement Disorders</i> , 2000, 15, 862-868.	2.2	45
432	Evaluation of Therapeutic Strategies: A New Method for Balancing Risk and Benefit. <i>Value in Health</i> , 2000, 3, 12-22.	0.1	9
433	Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 132-138.	1.1	5
434	Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 605-613.	1.1	109
435	Syntheses and biological activity of C-3-difluoromethyl-taxoids. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 1619-1628.	1.4	51
436	Consequences of misspecifying assumptions in nonlinear mixed effects models. <i>Computational Statistics and Data Analysis</i> , 2000, 34, 139-164.	0.7	48
437	Investigations using logistic regression models on the effect of the LMA on morphine induced vomiting after tonsillectomy. <i>Paediatric Anaesthesia</i> , 2000, 10, 633-638.	0.6	17

#	ARTICLE	IF	CITATIONS
438	Evaluation of pharmacokinetics and pharmacodynamics of captopril from transdermal hydrophilic gels in normotensive rabbits and spontaneously hypertensive rats. <i>International Journal of Pharmaceutics</i> , 2000, 209, 87-94.	2.6	22
439	Pharmacokinetic-Pharmacodynamic Modeling. <i>Archives of Medical Research</i> , 2000, 31, 539-545.	1.5	56
440	The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment. , 2000, 88, 33-58.		20
441	A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 304-311.	2.3	37
442	Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2000, 25, 49-58.	0.6	68
443	Prevention by theophylline of beta-2-receptor down regulation in healthy subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2000, 25, 179-188.	0.6	7
444	Metabolism and acid secretory effect of sulfated and nonsulfated gastrin-6 in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 279, G903-G909.	1.6	3
445	The Dose-Effect Relationship for Morphine and Vomiting after Day-Stay Tonsillectomy in Children. <i>Anaesthesia and Intensive Care</i> , 2000, 28, 155-160.	0.2	69
446	Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin. <i>Journal of Clinical Oncology</i> , 2000, 18, 195-195.	0.8	51
447	Antiplatelet Effects of MK-852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 496-507.	1.0	27
448	Postcesarean Epidural Morphine: A Dose-Response Study. <i>Anesthesia and Analgesia</i> , 2000, 9, 887-891.	1.1	43
449	Postantibiotic Suppression of Growth of Erythromycin A-Susceptible and -Resistant Gram-Positive Bacteria by the Ketolides Telithromycin (HMR 3647) and HMR 3004. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1749-1753.	1.4	23
450	Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2630-2637.	1.4	66
451	In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 943-949.	1.4	156
452	Modelling during drug development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2000, 50, 13-26.	2.0	32
453	Considerations on pharmacodynamics and pharmacokinetics: Can everything be explained by the extent of drug binding to its receptor?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2000, 78, 199-207.	0.7	5
454	Pharmacokinetic-Pharmacodynamic Modelling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen. <i>Clinical Pharmacokinetics</i> , 2000, 38, 505-518.	1.6	40
455	Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. <i>Annual Review of Pharmacology and Toxicology</i> , 2000, 40, 67-95.	4.2	316

#	ARTICLE	IF	CITATIONS
456	Simulation of Clinical Trials. Annual Review of Pharmacology and Toxicology, 2000, 40, 209-234.	4.2	248
457	Skin concentrations of H1-receptor antagonists. Journal of Allergy and Clinical Immunology, 2001, 107, 526-530.	1.5	46
458	Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers. Journal of Clinical Pharmacology, 2001, 41, 51-60.	1.0	54
459	Pharmacokinetic-Pharmacodynamic Modeling of the Antilipolytic Effects of an Adenosine Receptor Agonist in Healthy Volunteers. Journal of Clinical Pharmacology, 2001, 41, 61-69.	1.0	18
460	Concentration controlled therapy. International Congress Series, 2001, 1220, 135-144.	0.2	4
461	Angiotensin-converting enzyme inhibitors. Advances in Protein Chemistry, 2001, 56, 13-75.	4.4	48
463	A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine. Transplantation Proceedings, 2001, 33, 2557-2562.	0.3	2
464	Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. International Journal of Neuropsychopharmacology, 2001, 4, 207-15.	1.0	23
465	A Comparative Pharmacodynamic Study of the Arrhythmogenicity of Antidepressants, Fluvoxamine and Imipramine, in Guinea Pigs.. Biological and Pharmaceutical Bulletin, 2001, 24, 550-554.	0.6	12
466	Evaluation of the Method for Nifedipine Administration for a Rapid Onset of Clinical Effect: A Clinical Study in Normal Volunteers.. Yakugaku Zasshi, 2001, 121, 355-364.	0.0	11
467	Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep. American Journal of Veterinary Research, 2001, 62, 77-86.	0.3	24
468	Optimal Drug Therapy and Therapeutic Drug Monitoring After Spinal Cord Injury: A Population-Specific Approach. American Journal of Therapeutics, 2001, 8, 451-463.	0.5	9
469	Understanding hemodynamic responses to tracheal intubation. Canadian Journal of Anaesthesia, 2001, 48, 723-726.	0.7	11
470	Determination of enzyme (angiotensin convertase) inhibitors based on enzymatic reaction followed by HPLC. Journal of Pharmaceutical and Biomedical Analysis, 2001, 24, 1151-1156.	1.4	22
471	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. British Journal of Clinical Pharmacology, 2001, 51, 35-43.	1.1	14
472	Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. Paediatric Anaesthesia, 2001, 11, 205-213.	0.6	49
473	A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. Journal of Veterinary Pharmacology and Therapeutics, 2001, 24, 43-55.	0.6	53
474	Identifying the Neural Correlates of Consciousness: Strategies with General Anesthetics. Consciousness and Cognition, 2001, 10, 241-244.	0.8	2

#	ARTICLE	IF	CITATIONS
475	Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2001, 28, 7-25.	0.8	16
476	Bioavailability and bioequivalence: an FDA regulatory overview. <i>Pharmaceutical Research</i> , 2001, 18, 1645-1650.	1.7	169
477	Errors-in-Variables in Joint Population Pharmacokinetic/Pharmacodynamic Modeling. <i>Biometrics</i> , 2001, 57, 803-812.	0.8	20
478	Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK&PD model. <i>Computers in Biology and Medicine</i> , 2001, 31, 157-172.	3.9	76
479	Target concentration intervention: beyond Y2K. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 55-59.	1.1	5
480	Pharmacodynamic analysis of steroid 5 α -reductase inhibitory actions of Z-350 in rat prostate. <i>European Journal of Pharmacology</i> , 2001, 426, 105-111.	1.7	3
481	Using Simulations in the Design of an Anesthesia System. <i>Simulation and Gaming</i> , 2001, 32, 205-214.	1.2	0
482	DRUGTREATMENTEFFECTS ONDISEASEPROGRESSION. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 625-659.	4.2	151
483	P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 688-694.	1.3	32
484	Modeling of Relationships between Pharmacokinetics and Blockade of Agonist-Induced Elevation of Intraurethral Pressure and Mean Arterial Pressure in Conscious Dogs Treated with α 1-Adrenoceptor Antagonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 495-504.	1.3	19
485	Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. <i>British Journal of Cancer</i> , 2002, 87, 144-150.	2.9	44
486	Hyposomatotropism Blunts Lipolysis in Abdominally Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3851-3858.	1.8	14
487	Concentration&Effect Relation of Succinylcholine Chloride during Propofol Anesthesia. <i>Anesthesiology</i> , 2002, 97, 1082-1092.	1.3	31
488	Pharmacodynamics and Pharmacokinetic/Pharmacodynamic Relationships. , 2002, , 189-205.		0
489	Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. <i>Critical Care Medicine</i> , 2002, 30, 343-348.	0.4	65
490	A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 713-720.	1.5	31
491	Use of Sensitivity Functions to Characterise and Compare the Forgiveness of Drugs. <i>Clinical Pharmacokinetics</i> , 2002, 41, 371-380.	1.6	11
492	Pharmacokinetic-Pharmacodynamic Modelling of Magnesium Plasma Concentration and Blood Pressure in Preeclamptic Women. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1105-1113.	1.6	21

#	ARTICLE	IF	CITATIONS
493	Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. <i>AAPS PharmSci</i> , 2002, 4, 29-38.	1.3	16
494	Antihypertensive therapy: basic pharmacokinetic and pharmacodynamic principles as applied to infants and children*1. <i>American Journal of Hypertension</i> , 2002, 15, S34-S37.	1.0	10
495	Iontophoretic delivery of apomorphine:. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, S57-S75.	6.6	23
496	Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of baclofen in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2002, 27, 163-169.	0.6	5
497	Calculation of steady-state distribution delay between central and peripheral compartments in two-compartment models with infusion regimen. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2002, 27, 259-264.	0.6	5
498	Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 90, 327-332.	0.0	3
499	The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR α -ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. <i>British Journal of Cancer</i> , 2002, 86, 1472-1478.	2.9	24
500	Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. <i>Investigational New Drugs</i> , 2002, 20, 83-93.	1.2	10
501	Modeling the influence of growth hormone on lipolysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 157-170.	0.8	6
502	The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain. <i>Pharmaceutical Research</i> , 2003, 20, 1752-1759.	1.7	41
503	Investigation of the pharmaceutical and pharmacological equivalence of different Hawthorn extracts. <i>Phytomedicine</i> , 2003, 10, 8-16.	2.3	43
504	Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2003, 26, 139-150.	0.6	35
505	Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 520-525.	1.1	44
506	Do β -blockers prolong survival in heart failure only by inhibiting the β ₁ -receptor? A perspective on the results of the COMET trial. <i>Journal of Cardiac Failure</i> , 2003, 9, 429-443.	0.7	62
507	Aminoglycoside Dosages and Nephrotoxicity. <i>Clinical Pharmacokinetics</i> , 2003, 42, 493-500.	1.6	40
508	Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2118-2124.	1.4	322
509	Cytotoxic response of <i>Aspergillus fumigatus</i> -produced mycotoxins on growth medium, maize and commercial animal feed substrates. <i>Food and Chemical Toxicology</i> , 2003, 41, 395-403.	1.8	18
510	Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 498-506.	1.3	50

#	ARTICLE	IF	CITATIONS
511	Cellular issues relating to the resistance of HIV to antiretroviral agents. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 45-48.	1.5	4
512	Optimal Design for Estimating Parameters of the 4-Parameter Hill Model. <i>Nonlinearity in Biology, Toxicology, Medicine</i> , 2003, 1, 154014203902499.	0.4	29
513	Effects of Isoflurane and Propofol on Glutamate and GABA Transporters in Isolated Cortical Nerve Terminals. <i>Anesthesiology</i> , 2003, 98, 364-372.	1.3	40
514	The Influence of Hemorrhagic Shock on Propofol. <i>Anesthesiology</i> , 2003, 99, 409-420.	1.3	141
515	The Role of Pharmacometrics in Cardiovascular Drug Development. , 2003, , 365-388.		1
516	Bayesian Inference in Physiologically-based Pharmacokinetic Modeling: Application to Anticancer Drug Development. , 2004, , 105-131.		1
517	s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. <i>The Hematology Journal</i> , 2004, 5, 247-254.	2.0	19
518	Getting the best from pediatric pharmacokinetic data. <i>Paediatric Anaesthesia</i> , 2004, 14, 713-715.	0.6	23
519	Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal antibody for EGF/r3 antibody. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 261-270.	1.9	14
520	Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1825-1857.	6.6	255
521	Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004, 31, 243-268.	0.8	26
522	Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. <i>Statistics in Medicine</i> , 2004, 23, 531-544.	0.8	29
523	Synthesis, molecular modeling, and evaluation of nonphenolic indole analogs of mycophenolic acid. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 2867-2879.	1.4	23
524	Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. , 2004, , 333-372.		4
525	Clinical Pharmacology. <i>Drug Safety</i> , 2004, 27, 535-554.	1.4	32
526	Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid. <i>Clinical Pharmacokinetics</i> , 2004, 43, 467-478.	1.6	56
527	Subcutaneous Apomorphine. <i>Drugs and Aging</i> , 2004, 21, 687-709.	1.3	152
528	Optimizing dose selection with computer modeling and simulation: application to the vasopeptidase inhibitor m100240. <i>American Journal of Hypertension</i> , 2004, 17, S158.	1.0	0

#	ARTICLE	IF	CITATIONS
529	Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 621-631.	1.0	13
530	Pharmacokinetic and Pharmacodynamic Analysis of Amprenavir-Containing Combination Therapy in HIV-1-Infected Children. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1301-1308.	1.0	2
531	Drugs and Human Memory (Part 2). <i>Anesthesiology</i> , 2004, 100, 1277-1297.	1.3	50
532	Pharmacokinetics and Pharmacodynamics of Mivacurium in Patients Phenotypically Homozygous for the Atypical Plasma Cholinesterase Variant. <i>Anesthesiology</i> , 2005, 102, 1124-1132.	1.3	19
533	Treatment of Diffuse Basal Cell Carcinomas and Basaloid Follicular Hamartomas in Nevoid Basal Cell Carcinoma Syndrome by Wide-Area 5-Aminolevulinic Acid Photodynamic Therapy. <i>Archives of Dermatology</i> , 2005, 141, 60-7.	1.7	90
534	Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. <i>Blood</i> , 2005, 105, 1214-1221.	0.6	67
535	Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 378-387.	2.3	105
536	A model-based algorithm for the monitoring of long-term anticoagulation therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 915-921.	1.9	9
537	Influence of marbofloxacin on the pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 109-119.	0.6	26
538	Explicit solutions for a class of indirect pharmacodynamic response models. <i>Computer Methods and Programs in Biomedicine</i> , 2005, 77, 91-97.	2.6	5
539	Pharmacology. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1129-1139.	2.1	8
540	Applicability of microdialysis as a technique for pharmacokineticâ€“pharmacodynamic (PKâ€“PD) modeling of antihypertensive beta-blockers. <i>Journal of Pharmacological and Toxicological Methods</i> , 2005, 52, 244-250.	0.3	22
541	Pharmacokineticâ€“Pharmacodynamic Modeling of Opioids. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 90-103.	0.6	165
542	A Mathematical Model for Paroxetine Antidepressant Effect Time Course and Its Interaction with Pindolol. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 663-683.	0.8	12
543	Non-Linear Mixed Effects Modeling â€“ From Methodology and Software Development to Driving Implementation in Drug Development Science. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 161-183.	0.8	87
544	A semi-parametric approach to fitting a nonlinear mixed PK/PD model with an effect compartment using SAS. <i>Pharmaceutical Statistics</i> , 2005, 4, 59-69.	0.7	2
545	Misunderstandings regarding clinical cross-over trials. <i>Statistics in Medicine</i> , 2005, 24, 3675-3678.	0.8	6
546	Interstitial muscle concentrations of rocuronium under steady-state conditions in anaesthetized dogs: actual versus predicted values. <i>British Journal of Anaesthesia</i> , 2005, 94, 49-56.	1.5	14

#	ARTICLE	IF	CITATIONS
548	Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 209-219.	1.4	58
549	Impact of peripheral elimination on the concentrationâ€“effect relationship of remifentanyl in anaesthetized dogs â€“. British Journal of Anaesthesia, 2005, 94, 357-365.	1.5	14
550	Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. Aids, 2005, 19, 473-479.	1.0	14
551	Optimal Design for Goodness-of-Fit of the Michaelisâ€“Menten Enzyme Kinetic Function. Journal of the American Statistical Association, 2005, 100, 1370-1381.	1.8	40
552	Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids. Clinical Pharmacokinetics, 2005, 44, 61-98.	1.6	655
553	Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia. Clinical Pharmacokinetics, 2005, 44, 317-329.	1.6	10
554	Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years. Journal of Allergy and Clinical Immunology, 2005, 116, 355-361.	1.5	56
555	Clinical Pharmacokinetics. Clinical Pharmacokinetics, 2006, 45, 645-647.	1.6	1
556	Hypothesis Testing and Bayesian Estimation using a Sigmoid E max Model Applied to Sparse Dose-Response Designs. Journal of Biopharmaceutical Statistics, 2006, 16, 657-677.	0.4	44
557	Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. Research in Veterinary Science, 2006, 80, 79-90.	0.9	32
558	Impact of Hypothermia on the Response to Neuromuscular Blocking Drugs. Anesthesiology, 2006, 104, 1070-1080.	1.3	120
559	Pharmacologic Management of Dental Anxiety. Journal of Clinical Psychopharmacology, 2006, 26, 1-3.	0.7	7
560	Relevance of frequent Î¼-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics Journal, 2006, 6, 200-210.	0.9	80
561	Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease. Pharmaceutical Research, 2006, 23, 2050-2059.	1.7	47
562	Disease Progression and Pharmacodynamics in Parkinson Disease â€“ Evidence for Functional Protection with Levodopa and Other Treatments. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 281-311.	0.8	86
563	A Bayesian Design and Analysis for Dose-Response Using Informative Prior Information. Journal of Biopharmaceutical Statistics, 2006, 16, 695-709.	0.4	19
565	Dose Response: Pharmacokineticâ€“Pharmacodynamic Approach. , 2006, , 73-88.		5
566	Optimal Adaptive Design in Clinical Drug Development: A Simulation Example. Journal of Clinical Pharmacology, 2007, 47, 1231-1243.	1.0	26

#	ARTICLE	IF	CITATIONS
567	Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve. Journal of Biopharmaceutical Statistics, 2007, 17, 1097-1115.	0.4	49
568	Adaptive Designs for Dose-Finding Studies Based on Sigmoid E max Model. Journal of Biopharmaceutical Statistics, 2007, 17, 1051-1070.	0.4	53
569	Initiation of Warfarin in Hospitals. Clinical Medicine and Research, 2007, 5, 207-208.	0.4	0
570	Pharmacokinetic and Pharmacodynamic Properties of Lafutidine after Postprandial Oral Administration in Healthy Subjects: Comparison with Famotidine. Biological and Pharmaceutical Bulletin, 2007, 30, 1003-1006.	0.6	19
572	Pharmacokinetics and Pharmacodynamics of Propofol Microemulsion and Lipid Emulsion after an Intravenous Bolus and Variable Rate Infusion. Anesthesiology, 2007, 106, 924-934.	1.3	66
573	Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy. Journal of Biopharmaceutical Statistics, 2007, 17, 461-480.	0.4	123
574	Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development. Clinical Pharmacokinetics, 2007, 46, 713-737.	1.6	57
575	Pharmacokinetic Considerations inÂClinical Toxicology. Clinical Pharmacokinetics, 2007, 46, 897-939.	1.6	68
576	Dose-Effect and Concentration-Effect Analysis. , 2007, , 289-300.		4
577	Time Course of Drug Response. , 2007, , 301-311.		1
579	Morphine in Postoperative Patients: Pharmacokinetics and Pharmacodynamics of Metabolites. Anesthesia and Analgesia, 2007, 105, 70-78.	1.1	95
580	TK/TD doseâ€response modeling of toxicity. Environmetrics, 2007, 18, 515-525.	0.6	0
581	Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Critical Reviews in Oncology/Hematology, 2007, 63, 1-11.	2.0	28
582	Using Disease Progression Models as a Tool to Detect Drug Effect. Clinical Pharmacology and Therapeutics, 2007, 82, 81-86.	2.3	41
583	Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview. Clinical Pharmacology and Therapeutics, 2007, 82, 3-6.	2.3	29
584	Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. British Journal of Clinical Pharmacology, 2007, 63, 206-215.	1.1	42
585	Decreased Efficacy of GABAA-receptor Modulation by Midazolam in the Kainate Model of Temporal Lobe Epilepsy. Epilepsia, 2007, 48, 1378-1387.	2.6	4
586	Levodopa Slows Progression of Parkinsonâ€™s Disease. External Validation by Clinical Trial Simulation. Pharmaceutical Research, 2007, 24, 791-802.	1.7	59

#	ARTICLE	IF	CITATIONS
587	Modeling amantadine treatment of influenza A virus in vitro. <i>Journal of Theoretical Biology</i> , 2008, 254, 439-451.	0.8	114
588	Locomotor response to levodopa in fluctuating Parkinson's disease. <i>Experimental Brain Research</i> , 2008, 184, 469-478.	0.7	29
589	Disease progression, drug action and Parkinson's disease: Why time cannot be ignored. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 207-216.	0.8	36
590	The Hill equation: a review of its capabilities in pharmacological modelling. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 633-648.	1.0	645
591	THE VALIDATION OF A NEW VASCULAR DAMAGE ASSAY FOR PHOTODYNAMIC THERAPY AGENTS. <i>Photochemistry and Photobiology</i> , 1995, 62, 896-905.	1.3	23
592	Agreement between two methods for assessing bioequivalence of inhaled salbutamol. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 380-384.	1.1	9
593	Brain monitoring in dogs using the cerebral state index during the induction of anaesthesia via target-controlled infusion of propofol. <i>Research in Veterinary Science</i> , 2008, 85, 227-232.	0.9	14
594	Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1. <i>Pediatrics</i> , 2008, 122, 1182-1190.	1.0	148
595	A Perspective on the Use of Concentration-QT Modeling in Drug Development. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 9-12.	1.0	29
596	Multivariable LPV control of anesthesia delivery during surgery. , 2008, , .		12
597	Authors' Reply to Dr Cohen: "Scientific Standards: Critical Comments on the Pharmacoepidemiological Study of Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia". <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 462-464.	0.7	1
598	Pharmacologic Principles and Pain: Pharmacokinetics and Pharmacodynamics. , 2009, , 113-140.		2
599	Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 323-335.	1.0	9
600	Activity of Indenoisoquinolines against African Trypanosomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 123-128.	1.4	20
601	Ibuprofen, Pharmacokinetics and Pharmacodynamics in the Isolated Rabbit Heart. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 56, 99-107.	0.0	3
602	Felodipine, Pharmacodynamics and Pharmacokinetics in the Isolated Rabbit Heart. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 59, 17-26.	0.0	13
603	The time course of drug effects. <i>Pharmaceutical Statistics</i> , 2009, 8, 176-185.	0.7	15
604	A step towards effect-site target-controlled infusion with propofol in dogs: a PK model for propofol. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 182-188.	0.6	12

#	ARTICLE	IF	CITATIONS
605	Incorporating Physiological and Biochemical Mechanisms into Pharmacokineticâ€“Pharmacodynamic Models: A Conceptual Framework*. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 2-12.	1.2	21
606	A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10Åmg): PROLONGEDâ€“RELEASE VERSUS THE CONVENTIONAL FORMULATION. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 469-477.	0.9	8
607	Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the longâ€“chain triglyceride emulsion of propofol in beagle dogs. British Journal of Pharmacology, 2009, 158, 1982-1995.	2.7	21
608	Pharmacokinetic-Pharmacodynamic Modelling of the Antihistaminic (H1) Effect of Bilastine. Clinical Pharmacokinetics, 2009, 48, 543-554.	1.6	47
609	Dose-response relationships for enzyme replacement therapy with imiglucerase/algucerase in patients with Gaucher disease type 1. Genetics in Medicine, 2009, 11, 92-100.	1.1	94
610	A Novel Model for Individual Dosing Regimens Against PK-PD Correlation. , 2009, , .		0
611	Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias. Clinical Neuropharmacology, 2009, 32, 321-325.	0.2	2
612	EU Enlargement and Convergence. Eastern European Economics, 2009, 47, 28-56.	0.8	25
613	Adaptive Penalized<i>D</i>-Optimal Designs for Dose Finding Based on Continuous Efficacy and Toxicity. Statistics in Biopharmaceutical Research, 2010, 2, 182-198.	0.6	15
614	How Do We Use Drug Concentration Data to Improve the Treatment of Overdose Patients?. Therapeutic Drug Monitoring, 2010, 32, 300-304.	1.0	10
615	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drugâ€“Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder. Journal of Pharmacological Sciences, 2010, 112, 142-150.	1.1	32
616	Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies. AAPS Journal, 2010, 12, 592-601.	2.2	31
617	Pharmacodynamics of S-2150, a Simultaneous Calcium-blocking and Î±1-Inhibiting Antihypertensive Drug, in Rats. Journal of Pharmacy and Pharmacology, 2010, 52, 273-280.	1.2	0
618	Dosing dilemmas in obese children. Archives of Disease in Childhood: Education and Practice Edition, 2010, 95, 112-117.	0.3	73
619	Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability. Pediatric Cardiology, 2010, 31, 505-510.	0.6	7
620	An example of optimal phase II design for exposure response modelling. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 475-491.	0.8	4
621	Bioequivalence for Topical Productsâ€“An Update. Pharmaceutical Research, 2010, 27, 2590-2601.	1.7	56
622	Adaptive <i>D</i>-â€“Optimal designs for dose finding based on a continuous efficacy endpoint. Biometrical Journal, 2010, 52, 836-852.	0.6	15

#	ARTICLE	IF	CITATIONS
623	Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations.. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 11.	0.9	32
625	Understanding Developmental Pharmacodynamics. Paediatric Drugs, 2010, 12, 223-233.	1.3	55
626	Newly Identified Antibacterial Compounds Are Topoisomerase Poisons in African Trypanosomes. Antimicrobial Agents and Chemotherapy, 2010, 54, 620-626.	1.4	12
627	Achieving a Quantitative Understanding of Antiretroviral Drug Efficacy. Clinical Infectious Diseases, 2010, 51, 1105-1106.	2.9	3
628	Dose-Time-Effect Modeling for Cancer Cell Growth in In-vitro Experiments. Statistics in Biopharmaceutical Research, 2010, 2, 84-96.	0.6	0
630	The Killing of African Trypanosomes by Ethidium Bromide. PLoS Pathogens, 2010, 6, e1001226.	2.1	64
631	Effects of remifentanil on the minimum alveolar concentration of isoflurane in dogs. American Journal of Veterinary Research, 2010, 71, 150-156.	0.3	27
632	Bone Physiology, Disease and Treatment. Clinical Pharmacokinetics, 2010, 49, 89-118.	1.6	42
633	Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-Species Pharmacologic Exposure-Response Relationships. Annual Reports in Medicinal Chemistry, 2010, 45, 55-70.	0.5	37
634	Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy. Journal of Pharmacy and Pharmacology, 2010, 63, 58-64.	1.2	5
635	PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 239-245.	1.4	76
636	Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. Clinical Pharmacokinetics, 2011, 50, 809-822.	1.6	70
637	Anti-hypertensive Effect of Oral Controlled-release Microspheres Containing an ACE Inhibitor (Delapril Hydrochloride) in Rats. Journal of Pharmacy and Pharmacology, 2011, 46, 661-665.	1.2	9
638	Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells, Molecules, and Diseases, 2011, 46, 66-72.	0.6	95
639	Formulation-dependent Pharmacokinetics and Pharmacodynamics of Propofol in Rats. Journal of Pharmacy and Pharmacology, 2011, 50, 37-42.	1.2	61
641	Comparative Pharmacokinetic and Pharmacodynamic Properties of Oral and Intravenous (+)-Sotalol in Healthy Volunteers. Journal of Pharmacy and Pharmacology, 2011, 46, 600-605.	1.2	17
642	The pharmacokinetics and dynamics of Oxprenolol: a simulation study with six subjects. Journal of Pharmacy and Pharmacology, 2011, 37, 802-806.	1.2	19
643	A Pharmacodynamic Model to Predict the Time Dependent Adaptation of Dopaminergic Activity During Constant Concentrations of Haloperidol*. Journal of Pharmacy and Pharmacology, 2011, 42, 566-571.	1.2	4

#	ARTICLE	IF	CITATIONS
644	A Pharmacokinetic-pharmacodynamic Linking Model for the \pm 2-Adrenergic Antagonism of Idazoxan on Clonidine-induced Mydriasis in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 47, 157-161.	1.2	4
645	Relationship Between Paracetamol Plasma Levels and its Analgesic Effect in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 741-744.	1.2	24
646	Explaining the acetaminophen-ibuprofen analgesic interaction using a response surface model. <i>Paediatric Anaesthesia</i> , 2011, 21, 1234-1240.	0.6	44
647	Understanding the time course of pharmacological effect: a PKPD approach. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 815-823.	1.1	74
648	Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary report. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 506-513.	1.9	17
650	Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models"; <i>Clin Pharmacokin</i> 6:429-453 (1981)"The Backstory. <i>AAPS Journal</i> , 2011, 13, 662-664.	2.2	23
651	The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 41-61.	0.8	61
653	The Pharmacokinetics and Pharmacological Effect of (S)-5-OH-DPAT Following Controlled Delivery with Transdermal Iontophoresis. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2996-3009.	1.6	5
654	Interpreting the results of Parkinson's disease clinical trials: Time for a change. <i>Movement Disorders</i> , 2011, 26, 569-577.	2.2	25
655	Mechanistic population modeling of diabetes disease progression in Goto-Kakizaki rat muscle. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 50-63.	1.1	2
656	Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. <i>Journal of Theoretical Biology</i> , 2011, 269, 234-244.	0.8	42
657	Characterization of the Analgesic Effects of Paracetamol and Caffeine Combinations in the Pain-induced Functional Impairment Model in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 627-631.	1.2	29
658	Model-Based Bayesian Adaptive Dose-Finding Designs for a Phase II Trial. <i>Statistics in Biopharmaceutical Research</i> , 2011, 3, 276-287.	0.6	9
659	Assessing the efficacy of molecularly targeted agents by using Kalman filter. , 2011, , .		2
660	∞ -adaptive methods for control of patient response to anesthesia. , 2011, , .		5
661	Rebuttal to the Response of Chou. <i>Cancer Research</i> , 2011, 71, 2798-2800.	0.4	2
662	A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs. <i>Science Translational Medicine</i> , 2011, 3, 91ra63.	5.8	62
663	Influence of casting method on effectiveness of foot orthoses using plantar pressure distribution. <i>Prosthetics and Orthotics International</i> , 2011, 35, 411-417.	0.5	5

#	ARTICLE	IF	CITATIONS
664	Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7613-7618.	3.3	99
665	Long-Term Maternal Hypoxia. Reproductive Sciences, 2011, 18, 948-962.	1.1	28
666	A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens—a Modeling Study of Drug Effects on Tumor Growth using Hybrid Systems. Cancer Informatics, 2012, 11, CIN.S8185.	0.9	7
667	Safe and Effective Variability—A Criterion for Dose Individualization. Therapeutic Drug Monitoring, 2012, 34, 565-568.	1.0	75
668	Designing Phase 2 Trials Based on Program-Level Considerations: A Case Study for Neuropathic Pain. Drug Information Journal, 2012, 46, 439-454.	0.5	24
669	Enhanced Sensitivity to Drug-induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction. Journal of Clinical Pharmacology, 2012, 52, 1296-1305.	1.0	16
670	Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its Fragment in an Immunocompetent Mouse Model. ISRN Pharmacology, 2012, 2012, 1-8.	1.6	6
672	Control of Patient Response to Anesthesia using Adaptive Methods. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 391-396.	0.4	3
673	AZD-3043. Anesthesiology, 2012, 116, 1267-1277.	1.3	35
674	Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 759-768.	2.4	28
675	Dose-Effect and Concentration-Effect Analysis. , 2012, , 343-356.		5
676	Disease Progress Models. , 2012, , 369-379.		1
677	Time Course of Drug Response. , 2012, , 357-367.		0
678	Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring. Analyst, The, 2012, 137, 2344.	1.7	131
679	A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature Medicine, 2012, 18, 446-451.	15.2	143
680	Investigation of 3-debenzoyl-(3-([124I]-iodobenzoyl))paclitaxel analog as a radio-tracer to study multidrug resistance in vivo. Applied Radiation and Isotopes, 2012, 70, 1624-1631.	0.7	3
681	Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. European Journal of Clinical Pharmacology, 2012, 68, 1473-1481.	0.8	2
682	Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-14.	1.3	336

#	ARTICLE	IF	CITATIONS
683	Dynamical modeling of drug effect using hybrid systems. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , 2012, 2012, 19.	1.4	6
684	Itraconazole and domperidone: a placebo-controlled drug interaction study. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1287-1294.	0.8	15
685	Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. <i>BMC Genomics</i> , 2012, 13, S11.	1.2	7
686	The Pharmacological Properties and Therapeutic Use of Apomorphine. <i>Molecules</i> , 2012, 17, 5289-5309.	1.7	65
687	Biomarkers and Therapeutic Drug Monitoring in Psychiatry. , 0, , .		3
688	An agenda for UK clinical pharmacology: Monitoring drug therapy. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 917-923.	1.1	27
689	<i>In Vitro</i> Bioequivalence Approach for a Locally Acting Gastrointestinal Drug: Lanthanum Carbonate. <i>Molecular Pharmaceutics</i> , 2013, 10, 544-550.	2.3	16
690	Metrics other than potency reveal systematic variation in responses to cancer drugs. <i>Nature Chemical Biology</i> , 2013, 9, 708-714.	3.9	280
691	Robust identification of molecularly targeted drug effect coefficient using H _∞ filter. , 2013, , .		0
692	Understanding the pharmacokinetics of anxiolytic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 423-440.	1.5	75
693	Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1339-1346.	1.4	25
694	Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics. , 2013, , 20-42.		3
695	Assessing Mathematical Models of Influenza Infections Using Features of the Immune Response. <i>PLoS ONE</i> , 2013, 8, e57088.	1.1	96
697	Meta-Analysis of Clinical Dose-Response in a Large Drug Development Portfolio. <i>Statistics in Biopharmaceutical Research</i> , 2014, 6, 302-317.	0.6	55
698	Relationship Between Blood Levels and the Anti-Hyperalgesic Effect of Ketoprofen in the Rat. <i>Drug Development Research</i> , 2014, 75, 189-194.	1.4	3
699	Bioequivalence accomplishments, ongoing initiatives, and remaining challenges. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 2-12.	0.6	6
700	Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 133-144.	0.6	2
701	Modelling drug interaction using a fractional order pharmacokinetic model. , 2014, , .		4

#	ARTICLE	IF	CITATIONS
702	Fundamentals of Bioequivalence. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 29-53.	0.2	3
703	A new bounded log-linear regression model. <i>Metrika</i> , 2014, 77, 695-720.	0.5	2
704	Adaptive optimal designs for dose-finding studies based on sigmoid Emax models. <i>Journal of Statistical Planning and Inference</i> , 2014, 144, 188-197.	0.4	7
705	Pharmacokinetics. <i>Biochemical Pharmacology</i> , 2014, 87, 93-120.	2.0	215
706	Photopharmacology: Beyond Proof of Principle. <i>Journal of the American Chemical Society</i> , 2014, 136, 2178-2191.	6.6	875
707	A linearization approach for the model-based analysis of combined aggregate and individual patient data. <i>Statistics in Medicine</i> , 2014, 33, 1460-1476.	0.8	8
708	Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. <i>Biochemical Journal</i> , 2014, 462, 475-487.	1.7	502
709	The acute effects of daily nicotine intake on heart rate – A toxicokinetic and toxicodynamic modelling study. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 70, 312-324.	1.3	11
710	Viral kinetic modeling: state of the art. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 431-443.	0.8	82
712	Estimation of Patient Sensitivity to Drug Effect during Propofol Hypnosis. , 2015, , .		16
713	Simultaneous estimation of parameters in the bivariate Emax model. <i>Statistics in Medicine</i> , 2015, 34, 3714-3723.	0.8	1
714	Network pharmacodynamic models for customized cancer therapy. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2015, 7, 243-251.	6.6	11
715	The efficacy of 2-nitrovinylfuran derivatives against <i>Leishmania</i> in vitro and in vivo. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 166-173.	0.8	9
716	Pharmacokinetic-pharmacodynamic relationship of anesthetic drugs: from modeling to clinical use. <i>F1000Research</i> , 2015, 4, 1289.	0.8	7
717	Considerations for designing chemical screening strategies in plant biology. <i>Frontiers in Plant Science</i> , 2015, 6, 131.	1.7	36
718	Determining drug efficacy parameters for mathematical models of influenza. <i>Journal of Biological Dynamics</i> , 2015, 9, 332-346.	0.8	17
719	Pharmacodynamic response modelling of arterial blood pressure in adult volunteers during propofol anaesthesia. <i>British Journal of Anaesthesia</i> , 2015, 115, 213-226.	1.5	14
720	Comparative pharmacokinetic and pharmacodynamic response of single and double intraruminal doses of ivermectin and moxidectin in nematode-infected lambs. <i>New Zealand Veterinary Journal</i> , 2015, 63, 227-234.	0.4	17

#	ARTICLE	IF	CITATIONS
721	A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 189-197.	0.6	4
722	Kinetic model selection and the Hill model in geochemistry. <i>International Journal of Environmental Science and Technology</i> , 2015, 12, 2545-2558.	1.8	31
723	Molecular mechanism matters: Benefits of mechanistic computational models for drug development. <i>Pharmacological Research</i> , 2015, 99, 149-154.	3.1	30
724	Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1393-1408.	1.5	14
725	Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 97-107.	1.1	13
726	Role of Apomorphine in the Treatment of Parkinson's Disease. <i>CNS Drugs</i> , 2015, 29, 83-89.	2.7	40
727	Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 211-224.	0.8	2
728	Quantifying the impact of drug combination regimens on TB treatment efficacy and multidrug resistance probability. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv247.	1.3	2
729	Clinical pharmacology = disease progression + drug action. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 18-27.	1.1	33
730	Pharmacokinetic-Pharmacodynamic Modeling to Study the Antipyretic Effect of Qingkailing Injection on Pyrexia Model Rats. <i>Molecules</i> , 2016, 21, 317.	1.7	24
731	Dose-response meta-analysis of differences in means. <i>BMC Medical Research Methodology</i> , 2016, 16, 91.	1.4	94
732	The History of Target-Controlled Infusion. <i>Anesthesia and Analgesia</i> , 2016, 122, 56-69.	1.1	105
733	In Reply. <i>Anesthesiology</i> , 2016, 124, 1417-1418.	1.3	0
734	Optimal designs for a multiresponse Emax model and efficient parameter estimation. <i>Biometrical Journal</i> , 2016, 58, 518-534.	0.6	5
735	A useful technique using imaging mass spectrometry for detecting the skin distribution of topically applied lidocaine. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 33, 157-163.	1.4	4
736	Consideraciones clínicas sobre la posología de los anticoagulantes orales de acción directa. <i>Revista Clínica Española</i> , 2016, 216, 384-392.	0.2	0
737	Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. <i>BMC Biology</i> , 2016, 14, 65.	1.7	65
738	Modeling Tumor Growth in Animals and Humans: An Evolutionary Approach. , 2016, , 209-235.		1

#	ARTICLE	IF	CITATIONS
739	Clinical considerations on the posology of direct oral anticoagulants. <i>Revista Clínica Española</i> , 2016, 216, 384-392.	0.3	0
740	Salbutamol has rapid onset pharmacodynamics as a bronchodilator. <i>Acta Anaesthesiologica Scandinavica</i> , 2016, 60, 1328-1331.	0.7	7
741	The Many Flavors of Model-Based Meta-Analysis: Part I-Introduction and Landmark Data. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 54-64.	1.3	35
742	Gaining Insights Into the Pharmacology of Anthelmintics Using <i>Haemonchus contortus</i> as a Model Nematode. <i>Advances in Parasitology</i> , 2016, 93, 465-518.	1.4	18
743	Bridging the Gap Between In-Vitro Dissolution and the Time Course of Ibuprofen-Mediating Pain Relief. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3658-3667.	1.6	13
744	Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 213-223.	0.6	28
745	Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 93-122.	1.3	248
746	A rolling-horizon pharmacokinetic pharmacodynamic model for warfarin inpatients in transient clinical states. <i>Personalized Medicine</i> , 2016, 13, 21-32.	0.8	0
747	Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 201-208.	1.0	17
748	Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. <i>Journal of Virology</i> , 2017, 91, .	1.5	57
749	The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients. <i>Scientific Reports</i> , 2017, 7, 40210.	1.6	14
750	Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥ 7 mg Daily: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 297-304.	2.3	16
751	The role of fractional calculus in modeling biological phenomena: A review. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2017, 51, 141-159.	1.7	448
752	Rational Selection and Use of Antimicrobials in Patients with Burn Injuries. <i>Clinics in Plastic Surgery</i> , 2017, 44, 521-534.	0.7	11
753	Defining project efficiency, effectiveness and efficacy. <i>International Journal of Managing Projects in Business</i> , 2017, 10, 621-641.	1.3	28
754	Design a Proof of Concept Trial. <i>ICSA Book Series in Statistics</i> , 2017, , 75-92.	0.0	1
755	Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2347-2355.	1.1	9
756	Allometric size: The scientific theory and extension to normal fat mass. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S59-S64.	1.9	88

#	ARTICLE	IF	CITATIONS
757	Development of an immunoassay for fluvoxamine detection using a recombinant single-chain variable fragment antibody. <i>Forensic Toxicology</i> , 2017, 35, 301-308.	1.4	1
758	Allopurinol: insights from studies of dose-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 449-462.	1.5	21
759	Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 962-975.	1.1	18
760	What is the best size predictor for dose in the obese child?. <i>Paediatric Anaesthesia</i> , 2017, 27, 1176-1184.	0.6	47
761	Toxic Assessment of Cadmium Based on Online Swimming Behavior and the Continuous AChE Activity in the Gill of Zebrafish (<i>Danio rerio</i>). <i>Water, Air, and Soil Pollution</i> , 2017, 228, 1.	1.1	29
762	In-host modeling. <i>Infectious Disease Modelling</i> , 2017, 2, 188-202.	1.2	45
763	Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 253-261.	1.9	0
764	A Ballooned Beta-Logistic Model. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 98-106.	0.6	1
765	Does time difference of the acetylcholinesterase (AChE) inhibition in different tissues exist? A case study of zebra fish (<i>Danio rerio</i>) exposed to cadmium chloride and deltamethrin. <i>Chemosphere</i> , 2017, 168, 908-916.	4.2	38
766	Single toxin dose-response models revisited. <i>Toxicology and Applied Pharmacology</i> , 2017, 314, 12-23.	1.3	10
767	Anesthesiologist in the Loop and Predictive Algorithm to Maintain Hypnosis While Mimicking Surgical Disturbance. <i>IFAC-PapersOnLine</i> , 2017, 50, 15080-15085.	0.5	23
768	Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 20, 226.	0.9	13
769	Bioinformatics and Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1709-1726.	1.0	128
770	Parameter estimation for sigmoid E_{max} models in exposure-response relationship. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 74.	0.3	7
771	Many Flavors of Model-Based Meta-Analysis: Part II Modeling Summary Level Longitudinal Responses. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 288-297.	1.3	13
772	The impact of non-genetic heterogeneity on cancer cell death. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2018, 53, 99-114.	2.3	41
773	Metabolomic analysis of short-term sulfamethazine exposure on marine medaka (<i>Oryzias melastigma</i>) by comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry. <i>Aquatic Toxicology</i> , 2018, 198, 269-275.	1.9	24
774	Clinical dose-response for a broad set of biological products: A model-based meta-analysis. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2694-2721.	0.7	10

#	ARTICLE	IF	CITATIONS
775	Experimental conditions affecting the kinetics of aqueous HCN polymerization as revealed by UV-vis spectroscopy. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2018, 191, 389-397.	2.0	14
776	Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates. <i>Angewandte Chemie</i> , 2018, 130, 272-277.	1.6	13
777	Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 266-271.	7.2	72
778	The Monitoring and Assessment of Cd ²⁺ Stress Using Zebrafish (<i>Danio rerio</i>). , 2018, , .		1
779	Investigating Different Mechanisms of Action in Combination Therapy for Influenza. <i>Frontiers in Pharmacology</i> , 2018, 9, 1207.	1.6	19
780	Multiscale Tumor Modeling With Drug Pharmacokinetic and Pharmacodynamic Profile Using Stochastic Hybrid System. <i>Cancer Informatics</i> , 2018, 17, 117693511879026.	0.9	10
781	Regional Multi-Armed Bandits With Partial Informativeness. <i>IEEE Transactions on Signal Processing</i> , 2018, 66, 5705-5717.	3.2	11
782	Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 354-362.	0.9	14
783	Stimulus-Response Mechanisms: An Overview. , 2018, , 161-170.		0
784	Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 621-635.	0.8	5
785	Modeling of fusion inhibitor treatment of RSV in African green monkeys. <i>Journal of Theoretical Biology</i> , 2018, 456, 62-73.	0.8	14
786	Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2519-2530.	1.6	15
787	Modeling the therapeutic efficacy of NF- κ B synthetic decoy oligodeoxynucleotides (ODNs). <i>BMC Systems Biology</i> , 2018, 12, 4.	3.0	10
788	A quantitative assessment of dynamical differences of RSV infections in vitro and in vivo. <i>Virology</i> , 2018, 523, 129-139.	1.1	10
789	Pharmacokinetics and Pharmacology of Drugs Used in Children. , 2019, , 100-176.e45.		5
790	Total Intravenous Anesthesia and Target-Controlled Infusion. , 2019, , 177-198.e3.		0
791	Pharmacokinetics and Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin and Piperaquine on Mosquitocidal Activity and QT Prolongation (IVERMAL). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 388-401.	2.3	28
792	Optimal designs for frequentist model averaging. <i>Biometrika</i> , 2019, 106, 665-682.	1.3	2

#	ARTICLE	IF	CITATIONS
793	Effects of shiatsu on the health-related quality of life of a person with secondary progressive multiple sclerosis: A mixed methods N-of-1 trial within a whole systems research case study. <i>European Journal of Integrative Medicine</i> , 2019, 32, 101006.	0.8	3
794	Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 699-723.	1.2	16
795	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019, 103, 2012-2030.	0.5	43
796	Practicalities of Total Intravenous Anesthesia and Target-controlled Infusion in Children. <i>Anesthesiology</i> , 2019, 131, 164-185.	1.3	42
797	Pharmacokineticâ€“pharmacodynamic population modelling in paediatric anaesthesia and its clinical translation. <i>Current Opinion in Anaesthesiology</i> , 2019, 32, 353-362.	0.9	7
798	Pharmacokinetic and Pharmacodynamic Modelling in Anaesthesia. , 2019, , 14-28.		0
799	Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics. , 2019, , 20-43.		0
801	A Modelâ€“Based Metaâ€“Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1213-1223.	2.3	72
802	Pharmacokinetics and population pharmacokinetics in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28132.	0.8	7
803	Quantitative analysis of the placebo response in pharmacotherapy of insomnia and its application in clinical trials. <i>Sleep</i> , 2020, 43, .	0.6	11
804	Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics. <i>Drug Delivery</i> , 2020, 27, 1667-1675.	2.5	8
805	Pharmacokinetic-Pharmacodynamic Modeling of the Antioxidant Activity of Quzhou Fructus Aurantii Decoction in a Rat Model of Hyperlipidemia. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110646.	2.5	9
806	Functional assays to assess the therapeutic potential of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12033.	5.5	54
807	A Systematic Review and Meta-regression Analysis on the Impact of Increasing IgG Trough Level on Infection Rates in Primary Immunodeficiency Patients on Intravenous IgG Therapy. <i>Journal of Clinical Immunology</i> , 2020, 40, 682-698.	2.0	12
808	Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. <i>Frontiers in Neurology</i> , 2020, 11, 370.	1.1	7
809	Optimal Online Learning for Nonlinear Belief Models Using Discrete Priors. <i>Operations Research</i> , 2020, 68, 1538-1556.	1.2	3
810	Sex differences in pharmacokinetics predict adverse drug reactions in women. <i>Biology of Sex Differences</i> , 2020, 11, 32.	1.8	273
811	Pharmacokinetic and pharmacodynamic considerations of general anesthesia in pediatric subjects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 279-295.	1.5	5

#	ARTICLE	IF	CITATIONS
812	Age progression from vicenarians (20â€“29Âyear) to nonagenarians (90â€“99Âyear) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 145-161.	0.8	1
813	Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition. <i>Cell Death Discovery</i> , 2020, 6, 6.	2.0	13
814	Timeâ€“toâ€“Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 505-514.	1.0	42
815	Assessment of Similarity in Antipsychotic Exposureâ€“Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 848-859.	1.0	5
816	Concentrationâ€“Dependent Subcellular Distribution of Ultrasmall Nearâ€“Infraredâ€“Emitting Gold Nanoparticles. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 5739-5743.	7.2	29
817	Pharmacokinetics and Pharmacodynamics in the Pediatric Population. , 2021, , 247-271.		0
818	Oral Drug Delivery, Absorption and Bioavailability. , 2022, , 406-437.		3
819	Principles of pharmacokinetics and pharmacodynamics. , 2021, , 219-242.		0
820	Effects of Doxorubicin Delivery by Nitrogen-Doped Graphene Quantum Dots on Cancer Cell Growth: Experimental Study and Mathematical Modeling. <i>Nanomaterials</i> , 2021, 11, 140.	1.9	25
821	Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol?. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 305-317.	0.8	1
822	Concentrationâ€“Dependent Subcellular Distribution of Ultrasmall Nearâ€“Infraredâ€“Emitting Gold Nanoparticles. <i>Angewandte Chemie</i> , 2021, 133, 5803-5807.	1.6	8
823	Pharmacokineticâ€“pharmacodynamic modeling analysis and antiâ€“inflammatory effect of Wangbi capsule in the treatment of adjuvantâ€“induced arthritis. <i>Biomedical Chromatography</i> , 2021, 35, e5101.	0.8	9
824	Reducing Passive Drug Diffusion from Electrophoretic Drug Delivery Devices through Coâ€“lon Engineering. <i>Advanced Science</i> , 2021, 8, 2003995.	5.6	6
825	Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. <i>Respiratory Medicine</i> , 2021, 180, 106369.	1.3	9
826	Location matters: Overlooked ethnicâ€“geographic effect in China and Austria on propofol/cisatracurium sex differences among a population pharmacokinetic/pharmacodynamic (PopPK/PD) covariate analysis in men, women, and one transgender subject. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 182-198.	1.0	4
827	Is the N-of-1 method applicable in bodywork research? Lessons learned using a trial as a methodological pilot. <i>Journal of Integrative Medicine</i> , 2021, 19, 203-210.	1.4	0
828	Fast screening of covariates in population models empowered by machine learning. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 597-609.	0.8	28
829	Elezanumab, a human anti-RGMA monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. <i>Neurobiology of Disease</i> , 2021, 155, 105385.	2.1	14

#	ARTICLE	IF	CITATIONS
831	Concentrationâ€‘QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. British Journal of Clinical Pharmacology, 2021, , .	1.1	2
832	Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Evaluate the Absorption of Midazolam Rectal Gel. European Journal of Pharmaceutical Sciences, 2021, 167, 106006.	1.9	3
833	A Novel Approach to Assess the Potency of Topical Corticosteroids. Pharmaceutics, 2021, 13, 1456.	2.0	7
834	Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Doseâ€‘Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi). Methods in Molecular Biology, 2021, 2296, 393-408.	0.4	0
835	Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans. Archives of Dermatology, 1994, 130, 740-747.	1.7	21
838	The Bayesian approach to Population pharmacokinetic/pharmacodynamic modeling. Lecture Notes in Statistics, 1999, , 205-265.	0.1	26
839	In Vivo Pharmacodynamic Modeling for Drug Discovery. , 2012, , 1035-1054.		1
840	Bioequivalence of Topical Dermatological Products. , 1993, , 393-413.		3
841	Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies, and Innovative Approaches. , 2014, , 113-151.		4
842	Pharmacometrics in Cardiovascular Safety. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 189-227.	0.2	3
843	Antifolates in Combination Therapy. , 1999, , 365-382.		3
844	c-Optimal Designs for the Bivariate Emax Model. Contributions To Statistics, 2013, , 153-161.	0.2	8
845	Pharmacokinetics and Pharmacodynamics in the Pediatric Patient. , 2017, , 441-516.		2
846	Pharmacokineticâ€‘Pharmacodynamic Modelling of Anesthetic Drugs. , 2017, , 117-145.		1
847	Modeling and Control of Anesthetic Pharmacodynamics. , 2007, , 263-289.		5
848	General Principles of Pharmacokinetics. Handbook of Experimental Pharmacology, 2004, , 35-86.	0.9	4
849	Extracting Information from the Variance Function: Optimal Design. Contributions To Statistics, 2001, , 45-52.	0.2	11
850	Concepts for Toxicokinetic-Toxicodynamic Modelling in Clinical Toxicology: Application to Acute Cardiac Glycoside Intoxications. Archives of Toxicology Supplement, 1992, 15, 253-256.	0.7	6

#	ARTICLE	IF	CITATIONS
851	Opioid Analgesics in Clinical Pain Management. Handbook of Experimental Pharmacology, 1993, , 697-743.	0.9	19
852	Time Course of Drug Effect. Handbook of Experimental Pharmacology, 1994, , 333-352.	0.9	4
854	Clinical utility and limitations of pharmacokinetics. , 1983, , 397-414.		5
855	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 34, 103-108.	1.1	1
856	Pharmacokinetic Criteria for Drug Research and Development. Advances in Drug Research, 1990, 19, 1-138.	0.8	12
857	Pharmacology of Muscle Relaxants and Their Antagonists. , 2010, , 859-911.		54
858	Disease Progress Models. , 2007, , 313-321.		4
859	In Vitro Models for Prediction of Antimicrobial Activity: a Pharmacokinetic and Pharmacodynamic Perspective. Journal of Chemotherapy, 1997, 9, 55-63.	0.7	10
860	An Overview of Remifentanyl. Anesthesia and Analgesia, 1999, 89, 1.	1.1	135
861	Orally Administered Progesterone Enhances Sensitivity to Triazolam in Postmenopausal Women. Journal of Clinical Psychopharmacology, 1995, 15, 3-11.	0.7	43
862	Pharmacokinetics and Pharmacodynamics of Triazolam After Two Intermittent Doses in Obese and Normal-Weight Men. Journal of Clinical Psychopharmacology, 1995, 15, 197-205.	0.7	41
863	Antifibrillatory Effect of Esmolol Alone and in Combination with Lidocaine. Journal of Cardiovascular Pharmacology, 1996, 27, 376-382.	0.8	9
864	Quinidine Pharmacodynamics in Normal and Isoproterenol-Induced Hypertrophied Blood-Perfused Working Rabbit Hearts. Journal of Cardiovascular Pharmacology, 1996, 27, 916-926.	0.8	10
865	Endothelium-Dependent Vasodilation in Well-Developed Coronary Collateral Vessels. Journal of Cardiovascular Pharmacology, 1996, 28, 488-493.	0.8	6
866	SC-52458, an Orally Active Angiotensin II-Receptor Antagonist: Inhibition of Blood Pressure Response to Angiotensin II Challenges and Pharmacokinetics in Normal Volunteers. Journal of Cardiovascular Pharmacology, 1997, 29, 444-450.	0.8	11
867	THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT. Transplantation, 1996, 62, 1109-1112.	0.5	34
868	Exposureâ€“Response Relationship of Tranexamic Acid in Cardiac Surgery. Anesthesiology, 2021, 134, 165-178.	1.3	37
870	Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrobial Agents and Chemotherapy, 1997, 41, 2527-2532.	1.4	12

#	ARTICLE	IF	CITATIONS
871	In vitro pharmacodynamics of ceftazidime against <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2053-2056.	1.4	77
872	Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.. <i>Journal of Clinical Investigation</i> , 1984, 73, 539-547.	3.9	63
873	Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1399-1418.	1.0	145
874	Pharmacokinetics/Pharmacodynamics in Drug Development: An Industrial Perspective. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1428-1438.	1.0	26
875	Modeling and Simulation of Clinical Trials. <i>Drugs and the Pharmaceutical Sciences</i> , 2002, , .	0.1	1
876	Skin Transport. <i>Drugs and the Pharmaceutical Sciences</i> , 2002, , 88-194.	0.1	29
877	Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. <i>PLoS ONE</i> , 2015, 10, e0126647.	1.1	11
878	The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope. <i>PLoS ONE</i> , 2016, 11, e0149467.	1.1	6
879	Levodopa for the treatment of Parkinsonâ€™s disease: current perspectives. <i>Ageing Health</i> , 2006, 2, 101-109.	0.3	1
881	On optimal and suboptimal treatment strategies for a mathematical model of leukemia. <i>Mathematical Biosciences and Engineering</i> , 2013, 10, 151-165.	1.0	6
882	High-Sensitivity Assessment of Phagocytosis by Persistent Association-Based Normalization. <i>Journal of Immunology</i> , 2021, 206, 214-224.	0.4	13
883	Multi-Dimensional Column Chromatographic Method with UV Detection, for the Determination of Propranolol at Therapeutic Levels in Human Plasma. <i>Pharmaceutica Analytica Acta</i> , 2012, 3, .	0.2	4
884	Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of <i>In Vivo</i> Drug-Receptor Binding. <i>International Neurourology Journal</i> , 2012, 16, 107.	0.5	16
886	Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enersant: a human PET study with a novel H3 binding ligand, [11C]TASP457. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1127-1135.	3.3	3
887	Understanding the Dynamics of Dosage Response: A Nonlinear Meta-Analysis of Recent Reading Interventions. <i>Review of Educational Research</i> , 2022, 92, 209-248.	4.3	13
888	Statistical Analyses in Clinical PPK/PD Studies. Bridging Studies using NONMEM.. <i>Drug Metabolism and Pharmacokinetics</i> , 2000, 15, 363-370.	0.0	0
889	Practical Application of Pharmacokinetic-Pharmacodynamic Modeling.. <i>Drug Metabolism and Pharmacokinetics</i> , 2000, 15, 452-460.	0.0	0
890	Academic Perspective. <i>Drugs and the Pharmaceutical Sciences</i> , 2002, , .	0.1	0

#	ARTICLE	IF	CITATIONS
891	Population PK/PD Approach. Japanese Journal of Biometrics, 2003, 24, S85-S98.	0.0	0
892	Acute Effects of High-Dose Furosemide on Residual Renal Function in CAPD Patients. Peritoneal Dialysis International, 2003, 23, 339-347.	1.1	51
893	Pharmacometric Knowledge-Based Oncology Drug Development. , 2004, , 149-167.		1
894	The Assessment of Pharmacokinetics in Early-Phase Drug Evaluation. , 2005, , 123-132.		0
895	PHARMACODYNAMICS. , 2009, , 203-218.		0
896	Chapter 35. Correlation of Clinical Response with Drug Disposition. , 2009, , .		0
897	Clinical Pharmacology and Anticancer Drugs. , 2010, , 11-26.		0
898	Dose Response Analysis in Clinical Trials. , 2010, , 418-422.		0
900	Modeling the Progression of Disease. , 2011, , 57-90.		0
901	General Principles of Pharmacokinetics and Pharmacodynamics. , 2011, , 1253-1264.		1
902	Pharmacokinetics and Pharmacodynamics in the Pediatric Population. , 2012, , 123-143.		0
903	Population PK/PD Analysis. , 2012, , 1026-1033.		0
904	Factors Predicting Blood Pressure Response to Treatment. , 2013, , 107-113.		0
905	A Pharmacodynamic Model for Thiazinamium in Asthmatic Patients. , 1984, , 504-507.		0
906	Kinetics of Drug Action. , 1984, , 327-343.		3
907	Pharmacodynamic Considerations in the Development of New Drug Delivery Concepts. , 1985, , 13-33.		3
908	Clinical Decision Making Using Pharmacokinetic and Pharmacodynamic Data. , 1985, , 59-93.		3
909	Konzepte der klinischen Pharmakologie in der AnÄsthesiologie. , 1986, , 185-194.		0

#	ARTICLE	IF	CITATIONS
910	Design of Trials to Study Variability in Response: Statistical Aspects. , 1988, 24, 107-120.		0
911	Pharmacokinetics and diuretic effect of furosemide in liver cirrhosis patients.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1988, 19, 127-128.	0.1	0
912	Drug Concentration Monitoring. Progress in Clinical Biochemistry and Medicine, 1988, , 1-16.	0.5	1
913	Responsiveness to Calcium Antagonists in Essential Hypertension: Pharmacokinetic and Neurohumoral Aspects. , 1989, , 329-337.		0
914	Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments. , 1989, , 93-102.		0
915	Pharmacokinetic and Pharmacodynamic Modeling of Sedation in the ICU: Future Perspectives. Update in Intensive Care and Emergency Medicine, 1990, , 730-738.	0.6	0
916	Estimation of dose-response relationship through subject-specific dose-response curve. Oyo Tokeigaku, 1992, 21, 153-164.	0.2	0
917	Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik. , 1992, , 273-286.		0
918	Pharmacodynamics in healthy adults of a new Class III antiarrhythmic agent E4031.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1992, 23, 301-302.	0.1	0
919	Pharmacodynamics. Developments in Critical Care Medicine and Anesthesiology, 1992, , 87-115.	0.1	0
920	Erfassung und Darstellung von Konzentrations-Effekt- Beziehungen am Beispiel betamimetischer Substanzen. , 1993, , 33-39.		0
921	Methods to Facilitate Early Exploratory Testing of Novel Psychopharmacologic Agents in Humans. , 1993, 10, 111-123.		0
922	Pharmacoepidemiology, Population Pharmacokinetics and New Drug Development. , 1993, , 137-148.		0
923	Macrogol. , 1993, , 787-1056.		0
924	Effects of ageing on the effect of Atenolol.Study of the density - effect relation using effect compartment model.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1993, 24, 149-150.	0.1	0
925	Pharmacokinetic and Pharmacodynamic Modeling of Transdermal Products. , 1993, , 311-332.		3
926	Electroencephalographic Feedback Control of Anesthetic Drug Administration. , 1994, , 36-55.		0
927	Populaiton Pharmacodynamics of Vamicamide, a New Anticholinergic Drug, Analyzed by Nonlinear Mixed Effect Modeling. Relationship between the Average Urine Flow Rate and Serum Concentration in Healthy Volunteers.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1994, 25, 603-613.	0.1	0

#	ARTICLE	IF	CITATIONS
928	Model-Based Adaptive Control of Neuromuscular Blocking Agents. , 1995, , 223-233.		0
929	A New Approach to the Drug Evaluation: Population Pharmacokinetic and Pharmacodynamic(PK/PD) Analysis.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1996, 27, 741-757.	0.1	1
930	Pharmacokinetic-Pharmacodynamic Analysis of Respiratory Depression by Pentazocine in General Anesthesia Patients.. The Journal of Japan Society for Clinical Anesthesia, 1997, 17, 39-44.	0.0	0
931	Population Pharmacokinetics and Pharmacodynamics Analysis after a Single Intravenous Administration of Flecainide Acetate.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1997, 28, 1-14.	0.1	2
932	Evaluation of Pharmacokinetic-pharmacodynamic Relationship of Nitrazepam Using Computerized Eye Movement Analysis and Visual Analogue Scales in Healthy Japanese Volunteers.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1997, 28, 703-713.	0.1	3
933	Short-Term Myocardial Uptake of d- and l-Sotalol in Humans: Relation to Hemodynamic and Electrophysiologic Effects. Journal of Cardiovascular Pharmacology, 1998, 31, 876-884.	0.8	1
934	Murine Models of Pneumonia Using Aerosol Inoculation. , 1999, , 533-537.		0
935	Pharmacokinetics and Pharmacodynamics in the Pediatric Population. , 2015, , 173-193.		0
936	Furvina (G-1). Efectividad in vitro sobre Microorganismos Aislados de Infecciones DÃ©rmicas en Caninos. Revista De Investigaciones Veterinarias Del Peru, 2016, 27, 595.	0.0	1
938	Anticoagulation in Autoimmune Rheumatic Diseases. , 2020, , 159-179.		1
940	A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship. Anesthesia and Pain Medicine, 2020, 15, 1-7.	0.5	2
941	Dose-effect and concentration-effect analysis. , 2022, , 359-376.		2
942	Time course of drug response. , 2022, , 377-387.		0
943	Pharmacokineticâ€¦pharmacodynamic modelling of the antiâ€¦FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 116-128.	1.3	8
945	Pharmacotherapy of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 1986, 7, 657-671.	0.8	6
950	Pharmacodynamics in the elderly. Journal of the Royal Society of Medicine, 1994, 87 Suppl 23, 5-7.	1.1	3
951	Clinical pharmacokinetics: a simplified approach, Part 1. Journal of the National Medical Association, 1985, 77, 475-82.	0.6	4
952	Cocaine: analysis, pharmacokinetics, and metabolic disposition. Yale Journal of Biology and Medicine, 1988, 61, 105-13.	0.2	74

#	ARTICLE	IF	CITATIONS
953	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. American Journal of Cancer Research, 2011, 1, 925-54.	1.4	20
954	Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 34-91.	0.9	26
955	Disease progress models. , 2022, , 389-403.		1
956	The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. Drug Metabolism and Disposition, 2022, 50, 158-167.	1.7	11
957	Ultrasmall Luminescent Metal Nanoparticles: Surface Engineering Strategies for Biological Targeting and Imaging. Advanced Science, 2022, 9, e2103971.	5.6	29
958	Hydroxy Pentacyclic Triterpene Acid, Kaempferol, Inhibits the Human 5-Hydroxytryptamine Type 3A Receptor Activity. International Journal of Molecular Sciences, 2022, 23, 544.	1.8	13
959	Mathematical Modeling for an MTT Assay in Fluorine-Containing Graphene Quantum Dots. Nanomaterials, 2022, 12, 413.	1.9	4
960	Dose-independent drug release from 3D printed oral medicines for patient-specific dosing to improve therapy safety. International Journal of Pharmaceutics, 2022, 616, 121555.	2.6	18
961	Optimal control model of tumor treatment in the context of cancer stem cell. Mathematical Biosciences and Engineering, 2022, 19, 4627-4642.	1.0	1
962	Treatment of Respiratory Viral Coinfections. Epidemiologia, 2022, 3, 81-96.	1.1	1
966	Concerning Pharmacokinetics and Pharmacodynamics. , 0, , 337-360.		0
967	Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children. Pediatric Research, 2022, , .	1.1	0
968	Asn25 Deamidation as an Allosteric Tool to Increase IFN β -1a Biological Activity. Journal of Interferon and Cytokine Research, 2022, , .	0.5	0
969	Effect-site concentration of remimazolam at loss and recovery of responsiveness during general anesthesia: a simulation study. Anesthesia and Pain Medicine, 2022, 17, 262-270.	0.5	9
970	Classification of disease recurrence using transition likelihoods with expectationâ€œmaximization algorithm. Statistics in Medicine, 2022, 41, 4697-4715.	0.8	0
971	Drug Combination Modeling: Methods and Applications in Drug Development. Journal of Clinical Pharmacology, 2023, 63, 151-165.	1.0	11
972	Pharmacokinetics and Pharmacodynamics of Famotidine in Infants. Journal of Clinical Pharmacology, 1998, 38, 1089-1095.	1.0	23
973	The Relationship between Terazosin Dose and Blood Pressure Response in Hypertensive Patients. Journal of Clinical Pharmacology, 2000, 40, 1166-1172.	1.0	11

#	ARTICLE	IF	CITATIONS
974	Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis. Journal of Pharmacokinetics and Pharmacodynamics, 0, , .	0.8	0
975	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. Biotechnology and Genetic Engineering Reviews, 0, , 1-14.	2.4	0
976	Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD. Journal of Clinical Medicine, 2023, 12, 1642.	1.0	1
977	Perioperative Acetaminophen Dosing in Obese Children. Children, 2023, 10, 625.	0.6	1
978	Role of Bioinformatics in Drug Design and Discovery. , 2023, , 1-33.		0
983	The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. Nature Communications, 2023, 14, .	5.8	1